
<html lang="en"     class="pb-page"  data-request-id="fc387d88-d19e-4eb5-9a91-6590a4de9f47"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-9;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01655;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="Chelsea&#xA;E.  Powell" /></meta><meta name="dc.Creator" content="Yang  Gao" /></meta><meta name="dc.Creator" content="Li  Tan" /></meta><meta name="dc.Creator" content="Katherine A.  Donovan" /></meta><meta name="dc.Creator" content="Radosław&#xA;P.  Nowak" /></meta><meta name="dc.Creator" content="Amanda  Loehr" /></meta><meta name="dc.Creator" content="Magda  Bahcall" /></meta><meta name="dc.Creator" content="Eric S.  Fischer" /></meta><meta name="dc.Creator" content="Pasi A.  Jänne" /></meta><meta name="dc.Creator" content="Rani E.  George" /></meta><meta name="dc.Creator" content="Nathanael S.  Gray" /></meta><meta name="dc.Description" content="We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell..." /></meta><meta name="Description" content="We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 16, 2018" /></meta><meta name="dc.Type" content="rapid-communication" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01655" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01655" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01655" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01655" /></link>
        
    
    

<title>Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01655" /></meta><meta property="og:title" content="Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0007.jpeg" /></meta><meta property="og:description" content="We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01655"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01655">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01655&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01655&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01655&amp;href=/doi/10.1021/acs.jmedchem.7b01655" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4249-4255</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00408" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Brief Article</span><a href="/doi/10.1021/acs.jmedchem.8b00240" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chelsea E. Powell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chelsea E. Powell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chelsea%0AE.++Powell">Chelsea E. Powell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7624-1116" title="Orcid link">http://orcid.org/0000-0001-7624-1116</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Gao">Yang Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Tan">Li Tan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine A. Donovan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine A. Donovan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+A.++Donovan">Katherine A. Donovan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Radosław P. Nowak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Radosław P. Nowak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rados%C5%82aw%0AP.++Nowak">Radosław P. Nowak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amanda Loehr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amanda Loehr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amanda++Loehr">Amanda Loehr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Magda Bahcall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Magda Bahcall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Magda++Bahcall">Magda Bahcall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric S. Fischer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric S. Fischer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric+S.++Fischer">Eric S. Fischer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pasi A. Jänne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pasi A. Jänne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lowe Center for Thoracic Oncology,  Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pasi+A.++J%C3%A4nne">Pasi A. Jänne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rani E. George</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rani E. George</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute and Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rani+E.++George">Rani E. George</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Nathanael S. Gray</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nathanael S. Gray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#511f302539303f30343d0e1623302811353732387f393023273023357f343524"><span class="__cf_email__" data-cfemail="91dff0e5f9f0fff0f4fdced6e3f0e8d1f5f7f2f8bff9f0e3e7f0e3f5bff4f5e4">[email protected]</span></a>. Phone: (617) 582-8590.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nathanael+S.++Gray">Nathanael S. Gray</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5354-7403" title="Orcid link">http://orcid.org/0000-0001-5354-7403</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01655&amp;href=/doi/10.1021%2Facs.jmedchem.7b01655" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4249–4255</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 16, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 November 2017</li><li><span class="item_label"><b>Published</b> online</span>16 April 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 May 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01655" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01655</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4249%26pageCount%3D7%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChelsea%250AE.%2BPowell%252C%2BYang%2BGao%252C%2BLi%2BTan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D9%26contentID%3Dacs.jmedchem.7b01655%26title%3DChemically%2BInduced%2BDegradation%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D7%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4255%26publicationDate%3DMay%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01655"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4929</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">73</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01655" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chelsea\nE.&quot;,&quot;last_name&quot;:&quot;Powell&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;A. Donovan&quot;},{&quot;first_name&quot;:&quot;Radosław\nP.&quot;,&quot;last_name&quot;:&quot;Nowak&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;Loehr&quot;},{&quot;first_name&quot;:&quot;Magda&quot;,&quot;last_name&quot;:&quot;Bahcall&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;S. Fischer&quot;},{&quot;first_name&quot;:&quot;Pasi&quot;,&quot;last_name&quot;:&quot;A. Jänne&quot;},{&quot;first_name&quot;:&quot;Rani&quot;,&quot;last_name&quot;:&quot;E. George&quot;},{&quot;first_name&quot;:&quot;Nathanael&quot;,&quot;last_name&quot;:&quot;S. Gray&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;4249-4255&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01655&quot;},&quot;abstract&quot;:&quot;We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01655&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01655" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01655&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01655" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01655&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01655" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01655&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01655&amp;href=/doi/10.1021/acs.jmedchem.7b01655" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01655" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01655" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26pmid%3D29660984%26genre%3Darticle%26aulast%3DPowell%26date%3D2018%26atitle%3DChemically%2BInduced%2BDegradation%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D9%26spage%3D4249%26epage%3D4255%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/jmcmar.2018.61.issue-9/20180510/jmcmar.2018.61.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first identified in a chromosomal translocation associated with anaplastic large cell lymphoma (ALCL), a subtype of T-cell non-Hodgkin’s lymphoma.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Chromosomal translocations involving the kinase domain of ALK are seen in many cancers. In addition to ALCL, ALK fusion proteins are seen in diffuse large B-cell lymphoma (DLBCL), inflammatory myofibroblastic tumor (IMT), breast cancer, colorectal cancer, esophageal squamous cell cancer (ESCC), renal cell cancer (RCC), and non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> ALK fusion partners drive dimerization of the ALK kinase domain, leading to autophosphorylation, which in turn causes the kinase to become constitutively active.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Oncogenic ALK may also be expressed due to point mutations as is seen in neuroblastoma (NB), where germline mutations in ALK have been documented to drive the majority of hereditary NB cases.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Constitutively active oncogenic ALK signals through multiple pathways, including PI3K/AKT, RAS/ERK, and JAK/STAT3; this signaling leads to enhanced cell proliferation and survival.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">ALK is an attractive target for cancer therapies not only for its prominent role in a number of malignancies but also for its scant expression in normal adult tissue, which is restricted to a small subset of neural cells, reducing off-target toxicities of ALK-selective agents.<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2,7)</a> There are currently four FDA approved kinase inhibitors for the treatment of ALK-positive NSCLC: crizotinib, ceritinib (LDK378), alectinib, and most recently brigatinib. ALK-positive tumors are highly sensitive to ALK inhibition, indicating that these tumors are addicted to ALK kinase activity. However, despite initial dramatic responses of variable median duration (10.9 months for crizotinib; 16.6 months for ceritinib; 25.7 months for alectinib), resistance to therapy typically develops.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12">(8−12)</a></div><div class="NLM_p">While next-generation ALK inhibitors such as lorlatinib have been able to successfully target resistant tumors and have shown improvements in potency and overall response rates relative to approved inhibitors, resistance to these inhibitors still consistently arises in patients.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a> Therapeutic strategies that target ALK with a novel mechanism of action may provide ways to further delay the emergence of resistance mutations. Here we described the development and characterization of bivalent small molecules that are capable of inducing proteasome-mediated degradation of ALK.</div><div class="NLM_p">We developed small molecule degraders (also called PROTACs or degronimides) that are heterobifunctional small molecules that can induce degradation of a protein by bringing it into proximity of an E3 ligase.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> When the ternary complex is formed, the E3 ligase ubiquitinates the target protein, leading to its proteasomal degradation. It has recently been shown that this technology may be used to induce both kinase and kinase fusion protein degradation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">Here we present two examples of degraders that can induce ALK degradation in NSCLC cells expressing the fusion protein echinoderm microtubule-associated protein-like 4 (EML4)-ALK, ALCL cells expressing the fusion protein nucleophosmin (NPM)-ALK, and NB cells expressing ALK F1174L or ALK R1275Q.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We designed the degraders <b>9</b> and <b>11</b> based on known ALK inhibitors TAE684 and LDK378 (ceritinib), respectively, and used the cereblon ligand pomalidomide to recruit the E3 ubiquitin ligase complex (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). A 2-polyethylene glycol (PEG) linker was selected for these prototypical ALK degraders due to the success of a previously generated TAE684 based multikinase degrader.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> As control compounds to complement the degraders <b>9</b> and <b>11</b>, we designed the analogs <b>10</b> and <b>12</b> with des-carbonyl pomalidomide groups that exhibit substantially weakened binding to cereblon, as confirmed by a biochemical cereblon binding assay (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">S1</a>). Using an ALK activity assay, we validated that the degraders and their des-carbonyl counterparts are still able to bind ALK, with IC<sub>50</sub> values comparable to their parental kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Table S1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures and characterization of ALK degraders. (A) TAE684 is the parental kinase inhibitor of <b>9</b> and <b>10</b>. LDK378 is the parental inhibitor of <b>11</b> and <b>12</b>. <b>9</b> and <b>11</b> are ALK targeted degraders, while <b>10</b> and <b>12</b> contain des-carbonyl versions of the pomalidomide group, causing them to exhibit substantially weakened binding to cereblon. (B) TR-FRET ALK activity assay, plotted as the mean of three technical replicates ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We examined the effects of the degraders on cell proliferation in ALK-driven NSCLC line H3122, and ALCL lines Karpas 299 and SU-DHL-1. In NSCLC and ALCL cell lines the degraders and parental kinase inhibitors were about equipotent while the des-carbonyl compounds were less active than the inhibitors, indicating that the potent antiproliferative effects seen with the degraders are due in part to their ability to degrade ALK (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Antiproliferative best fit EC<sub>50</sub> values with 95% CI in NSCLC and ALCL cell lines after 72 h treatments (three biological replicates; Graphpad Prism 7 software).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next studied the induced degradation of ALK and a known off-target of TAE684 and LDK378, Aurora A kinase, in H3122 and Karpas 299 cells.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> A dose titration of <b>9</b> and <b>11</b> in each cell line for 16 h demonstrated that <b>9</b> is more selective for degradation of ALK versus Aurora A than <b>11</b>, which is consistent with LDK378’s higher selectivity for ALK compared to TAE684 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> From these dose titrations the DC<sub>50</sub> values of <b>9</b> and <b>11</b> against ALK were calculated to be the same in H3122 cells (10 nM, two independent experiments), while <b>11</b> induced more potent ALK degradation in Karpas 299 than <b>9</b> with DC<sub>50</sub> values of 40 nM and 180 nM, respectively (two independent experiments). Time course treatments with both degraders showed that some ALK degradation is observed at 4 h of treatment in H3122 cells and at 8 h of treatment in Karpas 299 cells, and maximum degradation is achieved at 16 h in both cases (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Degrader behavior in H3122 and Karpas 299 cells. (A) Immunoblots after 16 h of treatment with dose titrations of <b>9</b> and <b>11</b>. (B) Immunoblots after treatment with 250 nM compound for the indicated amount of time. (C) Immunoblots after 2 h pretreatments with DMSO, carfilzomib (Car), MLN4924 (MLN), pomalidomide (Pom), TAE684, or LDK378 followed by 16 h treatments with <b>9</b> or <b>11</b>. (D) Immunoblots of downstream ALK signaling after 16 h compound treatments; t-ALK indicates total ALK, and p-ALK indicates phosphorylated ALK. (E) Immunoblots of sustained downstream ALK signaling after the indicated treatment times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pretreatment of the cell lines with the proteasome inhibitor carfilzomib prevented degradation of ALK and Aurora A, validating that the degradation seen is occurring via the proteasome (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). MLN4924 indirectly inhibits the cereblon E3 ligase by blocking neddylation of the cullin RING ligase, CUL4, in the protein complex, which is required for ligase activity. Pretreatment with MLN4924 also prevented degradation of ALK and Aurora A, confirming that the degradation seen is occurring via recruitment of the cereblon E3 ligase complex (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Pretreatment with pomalidomide or the parental kinase inhibitor also prevented ALK degradation, although pretreatment with LDK378 only showed partial rescue in H3122 cells. This demonstrates that engagement of ALK and cereblon is required for the observed degradation.</div><div class="NLM_p">We compared the effects on downstream signaling between the parental kinase inhibitors, the degraders, and their des-carbonyl counterparts by examining ALK phosphorylation by Western blot after 16 h of treatment; this demonstrated that the extent of downstream signaling inhibition by the degraders is cell line dependent (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). In H3122 cells, <b>9</b> inhibited downstream signaling to a similar extent as its parental kinase inhibitor, while <b>11</b> showed improved downstream inhibition. In Karpas 299 cells the degraders affected downstream signaling to a lesser extent than the kinase inhibitors. In both cell lines the degraders affected downstream signaling more than their des-carbonyl counterparts, indicating that the degrader downstream effects are due to degradation and inhibition of ALK.</div><div class="NLM_p">When observing downstream signaling over a 48 h time course in H3122 cells, <b>9</b> sustained inhibition of ALK and STAT3 phosphorylation to a similar extent as TAE684, while <b>11</b> showed a distinct improvement on sustained inhibition compared to LDK378 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E). This is significant because inhibition of STAT3 signaling leads to significant antiproliferative effects in EML4-ALK expressing cells and sustained ALK pathway inhibition has been linked to greater antitumor efficacy.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a></div><div class="NLM_p">When we tested the antiproliferative effects of the degraders in NB cell lines, we observed an unreported, as of this writing, potential obstacle with the degrader technology related to the ATP-binding cassette subfamily B member 1 (ABCB1) drug transporter. We used Kelly and Lan5 lines, which are ABCB1 low expressing cells, and SH-SY5Y and CHLA20 lines, which are ABCB1 high expressing cells. ABCB1 has been shown to efflux hydrophobic and amphipathic compounds.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This drug transporter activity can be inhibited by tariquidar.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In the ABCB1 high expressing cells the degraders had low antiproliferative activity compared to the parental inhibitors. However, when we co-treated with tariquidar, we saw an increase in antiproliferative activity of the degraders with EC<sub>50</sub> values comparable to the parental kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In addition, knockdown of ABCB1 using shRNA also increased degrader-mediated ALK degradation and inhibition of proliferation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Figure S6</a>). Thus, we concluded that degraders can be substrates of the ABCB1 transporter. Future SAR efforts will need to focus on modifications to the degrader molecules that will prevent them from being effluxed by ABCB1 transporters.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Antiproliferative best fit EC<sub>50</sub> values with 95% CI in NB cell lines after 72 h treatments (two biological replicates; GraphPad Prism 7 software: ∗ = upper CI not calculated by model). 125 nM tariquidar (Tari.) was used for the indicated cotreatments. (B) Immunoblot of ABCB1 expression in NB lysates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next studied induced ALK degradation by immunoblots using Kelly and CHLA20 cells; CHLA20 cells were always co-treated with 125 nM tariquidar. In Kelly cells <b>9</b> and <b>11</b> were equipotent ALK degraders, with DC<sub>50</sub> values of 50 nM each as determined by Western blot after 16 h dose titrations (two independent experiments) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). As in the NSCLC and ALCL cell lines, <b>9</b> was less selective for ALK over Aurora A than <b>11</b> in both NB lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Time courses in the Kelly and CHLA20 cells showed that ALK degradation by the degraders could be observed after 4 h of treatment in CHLA20 and after 8 h in Kelly cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Interestingly, although pretreatment with carfilzomib, MLN4924, or pomalidomide in Kelly and CHLA20 cells did prevent Aurora A degradation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C), only pomalidomide and parental inhibitor pretreatment prevented ALK degradation. This may be due to carfilzomib and MLN4924 causing an upregulation of lysosomal degradation by suppressing the ubiquitin–proteasome system.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Degrader behavior in Kelly and CHLA20 cells. (A) Immunoblots after 16 h of treatment with dose titrations of <b>9</b> and <b>11</b>. Tari. indicates tariquidar. (B) Immunoblots after treatment with 100 nM compound for the indicated amount of time. (C) Immunoblots after 2 h pretreatments with DMSO, carfilzomib (Car), MLN4924 (MLN), pomalidomide (Pom), TAE684, or LDK378 followed by 16 h treatments with <b>9</b> and <b>11</b>. (D) Immunoblots of downstream ALK signaling after 16 h compound treatments; t-ALK indicates total ALK, and p-ALK indicates phosphorylated ALK. (E) Immunoblots of sustained downstream ALK signaling after the indicated treatment times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In Kelly cells <b>9</b> was equipotent to TAE684 at inhibiting downstream ALK signaling, while <b>11</b> was more potent than LDK378 at 16 h (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). In CHLA20 cells both degraders were more potent inhibitors of downstream ALK signaling than their parental inhibitors. <b>11</b> showed improved sustained inhibition of ALK phosphorylation compared to LDK378 in Kelly and CHLA20 cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E). In Kelly and CHLA20 cells STAT3 feedback signaling was activated by the parental inhibitors but not the degraders (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E). This observation indicates that STAT3 was not a downstream player in the antiproliferative effects observed in these cells and that kinase degraders may have the advantage of preventing feedback activation of STAT3 that has been previously reported as a major drawback of kinase-targeted therapeutics.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Expression proteomics was performed after 4 h of treatment with <b>9</b> and <b>11</b> in Kelly cells; this early time point was selected in order to minimize secondary effects. However, a decrease in ALK abundance was not measured at a significant level for either compound (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Figure S7</a>). The degradation of targets other than ALK, including PTK2, FER, RPS6KA1, and Aurora A, was measured at significant levels and confirmed by Western blot (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Figures S8, S9</a>); the degraded proteins detected by proteomics were shown during time courses to be more rapidly degraded than ALK, which may have resulted in the differences in detection by proteomics. PTK2, FER, and Aurora A have also been previously demonstrated to be very susceptible to kinase targeting degraders.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Interestingly, although <b>9</b> is a better inhibitor of RPS6KA1 than <b>11</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Table S2</a>), <b>11</b> is a better RPS6KA1 degrader (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Figures S7–S9</a>). These results highlight the importance of determining degrader selectivity profiles separately from their parental inhibitors. Since the ability to be degraded may vary for different protein targets, degrader selectivity must be carefully assessed. ALK degraders may be improved upon in the future by using more selective inhibitor scaffolds.</div><div class="NLM_p">The potential ability of degraders to overcome acquired resistance mutations was assessed using Ba/F3 cells expressing EML4-ALK with the resistant mutations L1196M, C1156Y, or G1202R (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">Figure S10</a>). <b>9</b> and <b>11</b> show a drop in antiproliferative activity similar to the behavior seen with the parental ALK inhibitors when EML4-ALK has a resistant mutation. Since <b>9</b> and <b>11</b> have demonstrated that ALK is amenable to small molecule induced degradation, it is likely that future ALK targeting degraders based on ALK inhibitors that are able to overcome resistance mutations may have improved pharmacodynamic properties in these resistant mutant cell lines.</div><div class="NLM_p last">While the efficacy of ALK degraders against resistant mutations must be explored further, this work does speak to potential challenges with resistance that may be inherent in the degrader technology since several processes must function together. In addition to the potential resistance by drug transporters demonstrated here, it is possible that factors such as cereblon down-regulation or deubiquitinase upregulation may impact degrader activity.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By linking known ALK inhibitors TAE684 and LDK378 to pomalidomide, we have provided prototypical examples that ALK degradation may be induced by E3 ligase recruitment in three major ALK-positive disease models. These compounds have displayed the ability to improve upon the pharmacodynamic properties of their parental inhibitors, especially sustained inhibition of downstream ALK signaling, indicating that degraders are a promising new avenue for targeted ALK therapies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, reagents and solvents were obtained from commercial suppliers and were used without further purification. <sup>1</sup>H NMR spectra were recorded on 500 MHz (Bruker A500), and chemical shifts are reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS). Coupling constants (<i>J</i>) are reported in Hz. Spin multiplicities are described as s (singlet), br (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Mass spectra were obtained on a Waters Micromass ZQ instrument. Preparative HPLC was performed on a Waters Sunfire C18 column (19 mm × 50 mm, 5 μm) using a gradient of 15–95% methanol in water containing 0.05% trifluoroacetic acid (TFA) over 22 min (28 min run time) at a flow rate of 20 mL/min. Purities of assayed compounds were in all cases greater than 95%, as determined by reverse-phase HPLC analysis.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <i>tert</i>-Butyl 4-(4-((5-Chloro-4-((2(isopropylsulfonyl)phenyl)amino)pyrimidin-2yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (<b>3</b>)</h3><div class="NLM_p last">Intermediate <b>1</b> was prepared according to the literature,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> while <i>tert</i>-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate (<b>2</b>) was commercially available. To <b>1</b> (693 mg, 2.0 mmol) and <b>2</b> (740 mg, 2.4 mmol) in <i>sec</i>-butanol (4 mL) was added TFA (185 μL, 2.4 mmol), and the mixture was stirred overnight at 80 °C. The mixture was then concentrated and purified by column chromatography (dichloromethane/methanol = 20:1) to yield 925 mg (75%) of <b>3</b> as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.54 (s, 1H), 8.60 (d, <i>J</i> = 8.4 Hz, 1H), 8.13 (s, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 7.91 (d, <i>J</i> 8.0 Hz, 1H), 7.62 (dd, <i>J</i> = 8.8, 8.4 Hz, 1H), 7.33 (s, 1H), 7.25 (dd, <i>J</i> = 8.4, 8.4 Hz, 1H), 6.55 (s, 1H), 6.47 (d, <i>J</i> = 8.8 Hz, 1H), 3.88 (s, 3H), 3.60 (m, 4H), 3.24 (m, 1H), 3.09 (m, 4H), 1.49 (s, 9H), 1.30 (d, <i>J</i> = 7.2 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 617 (M + H)<sup>+</sup>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>N</i><sup>2</sup>-(4-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)-5-chloro-<i>N</i><sup>4</sup>-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (<b>5</b>)</h3><div class="NLM_p last">To <b>3</b> (620 mg, 1.0 mmol) in dichloromethane (18 mL) TFA was added (1.8 mL), and the mixture was stirred at room temperature (rt) for 2 h, then was concentrated and dried under vacuum. To the obtained crude intermediate in acetonitrile (5 mL) were added commercially available bromide <b>4</b> (300 mg, 1.2 mmol) and potassium carbonate (414 mg, 3.0 mmol). The resulting mixture was stirred under 80 °C overnight, then cooled to rt and diluted with 50 mL of dichloromethane. The precipitation was filtered, and the filtrate was concentrated and purified by column chromatography (dichloromethane/methanol = 10:1) to yield 524 mg (78%) of <b>5</b> as a colorless oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H), 8.62 (d, <i>J</i> = 8.4 Hz, 1H), 8.13 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.62 (dd, <i>J</i> = 8.0, 8.0 Hz, 1H), 7.30 (m, 2H), 6.56 (s, 1H), 6.48 (d, <i>J</i> = 8.4 Hz, 1H), 3.88 (s, 3H), 3.70 (m, 10H), 3.25 (m, 1H), 3.41 (t, <i>J</i> = 5.2 Hz, 2H), 3.20 (m, 4H), 2.70 (m, 4H), 1.32 (d, <i>J</i> = 7.2 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 674 (M + H)<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> <i>tert</i>-Butyl (2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycinate (<b>7</b>)</h3><div class="NLM_p last">Intermediate <b>6</b> was prepared according to the literature.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To <b>6</b> (550 mg, 2.0 mmol) and glycine <i>tert</i>-butyl ester (260 mg, 2.0 mmol) in anhydrous DMSO (20 mL) was added <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA) (700 μL, 4.0 mmol). The reaction mixture was stirred under 90 °C for 1 day, then cooled down. The mixture was diluted with ethyl acetate (200 mL), washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated, purified by column chromatography (dichloromethane/ethyl acetate = 2:1) to yield 530 mg (68%) of <b>7</b> as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.06 (s, 1H), 7.51 (dd, <i>J</i> = 8.4, 7.2 Hz, 1H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 6.76 (d, <i>J</i> = 6.76 Hz, 1H), 4.93 (dd, <i>J</i> = 12.0, 6.4 Hz, 1H), 3.94 (s, 2H), 2.67–2.92 (m, 2H), 2.12 (m, 1H), 1.93 (m, 1H), 1.50 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 388 (M + H)<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> (2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine (<b>8</b>)</h3><div class="NLM_p last">To <b>7</b> (390 mg, 1.0 mmol) in dichloromethane (18 mL) was added TFA (1.8 mL). The mixture was stirred at rt overnight, then was concentrated and dried under vacuum to give <b>8</b> as a yellow solid, which was used in next step without purification. MS (ESI) <i>m</i>/<i>z</i> 330 (M – H)<sup>−</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>N</i>-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide (<b>9</b>)</h3><div class="NLM_p">Under a nitrogen atmosphere, to <b>5</b> (135 mg, 0.2 mmol) in tetrahydrofuran (18 mL) and water (1.8 mL) was added triphenylphosphine (63 mg, 0.24 mmol). The reaction mixture was stirred overnight, then concentrated and dried under vacuum. To the obtained crude oil in anhydrous dichloromethane (3 mL) were added <b>8</b> (73 mg, 0.22 mmol) and (1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate) (HATU) and DIEA (110 μL, 0.6 mmol). The reaction mixture was stirred for 2 h, then concentrated and purified by column chromatography (dichloromethane/methanol = 10:1) to yield 136 mg (71%) of <b>9</b> as a yellow foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.10 (s, 1H), 9.76 (br, 1H), 9.57 (s, 1H), 8.56 (br, 1H), 8.41 (H, 1H), 8.19 (s, 1H), 8.18 (m, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (m, 1H), 7.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 1H), 7.30 (dd, <i>J</i> = 8.0, 7.5 Hz, 1H), 7.07 (d, <i>J</i> = 7.0 Hz, 1H), 6.95 (m, 1H), 6.85 (d, <i>J</i> = 8.5 Hz, 1H), 6.71 (d, <i>J</i> = 2.5 Hz, 1H), 6.53 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 5.07 (dd, <i>J</i> = 13.0, 5.5 Hz, 1H), 3.94 (d, <i>J</i> = 5.0 Hz, 2H), 3.85 (m, 2H), 3.80 (m, 2H), 3.76 (s, 3H), 3.58 (m, 4H), 3.45 (m, 4H), 3.40 (m, 4H), 3.30 (m, 2H), 3.24 (m, 2H), 3.03 (m, 2H), 2.53–2.63 (m, 2H), 1.16 (d, <i>J</i> = 7.0 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 961 (M + H)<sup>+</sup>.</div><div class="NLM_p"><b>10</b>, <b>11</b>, and <b>12</b> were synthesized with similar procedures as <b>9</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>N</i>-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethoxy)ethoxy)ethyl)-2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)amino)acetamide (<b>10</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.78 (br, 1H), 9.59 (s, 1H), 8.55 (br, 1H), 8.44 (s, 1H), 8.20 (s, 1H), 8.18 (dd, <i>J</i> = 6.0, 5.5 Hz, 1H), 7.82 (s, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (m, 1H), 7.55 (dd, <i>J</i> = 8.0, 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (dd, <i>J</i> = 7.5, 7.5 Hz, 1H), 7.04 (d, <i>J</i> = 7.0 Hz, 1H), 6.95 (m, 1H), 6.82 (d, <i>J</i> = 8.5 Hz, 1H), 6.71 (d, <i>J</i> = 2.5 Hz, 1H), 6.53 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 4.52 (dd, <i>J</i> = 12.0, 6.5 Hz, 1H), 3.93 (d, <i>J</i> = 4.5 Hz, 2H), 3.85 (m, 2H), 3.80 (m, 2H), 3.77 (s, 3H), 3.60 (m, 4H), 3.57 (m, 2H), 3.46 (m, 4H), 3.40 (m, 2H), 3.30 (m, 2H), 3.22 (m, 2H), 3.03 (m, 2H), 2.20 (m, 1H), 1.96 (m, 1H), 1.89 (m, 2H), 1.16 (d, <i>J</i> = 6.5 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 947 (M + H)<sup>+</sup>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>N</i>-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide (<b>11</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.09 (s, 1H), 9.59 (s, 1H), 9.46 (s, 1H), 8.44 (d, <i>J</i> = 8.5 Hz, 1H), 8.38 (br, 1H), 8.25 (s, 1H), 8.18 (dd, <i>J</i> = 6.0, 5.5 Hz, 1H), 8.09 (s, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (dd, <i>J</i> = 8.5, 8.0 Hz, 1H), 7.57 (dd, <i>J</i> = 8.0, 7.5 Hz, 1H), 7.34 (dd, <i>J</i> = 8.5, 8.0 Hz, 1H), 7.06 (d, <i>J</i> = 6.0 Hz, 1H), 6.93 (dd, <i>J</i> = 5.5, 5.5 Hz, 1H), 6.84 (d, <i>J</i> = 9.0 Hz, 1H), 6.75 (s, 1H), 5.06 (dd, <i>J</i> = 13.0, 5.5 Hz, 1H), 4.48 (m, <i>J</i> = 6.0 Hz, 1H), 3.93 (d, <i>J</i> = 5.5 Hz, 2H), 3.78 (m, 2H), 3.59 (m, 4H), 3.56 (m, 2H), 3.44 (m, 4H), 3.28 (m, 2H), 3.13 (m, 4H), 2.83–2.99 (m, 2H), 2.52–2.61 (m, 1H), 2.13 (s, 3H), 1.85–2.04 (m, 4H), 1.22 (d, <i>J</i> = 6.0 Hz, 6H), 1.15 (d, <i>J</i> = 7.0 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 1002 (M + H)<sup>+</sup>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>N</i>-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)ethoxy)ethoxy)ethyl)-2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)amino)acetamide (<b>12</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 1H), 8.46 (d, <i>J</i> = 8.5 Hz, 1H), 8.25 (s, 1H), 8.16 (dd, <i>J</i> = 5.5, 5.0 Hz, 1H), 8.07 (s, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.81 (s, 1H), 7.61 (dd, <i>J</i> = 8.5, 8.0 Hz, 1H), 7.55 (dd, <i>J</i> = 8.0, 7.5 Hz, 1H), 7.52 (s, 1H), 7.35 (dd, <i>J</i> = 8.5, 8.0 Hz, 1H), 7.03 (d, <i>J</i> = 6.0 Hz, 1H), 6.93 (dd, <i>J</i> = 6.0, 5.5 Hz, 1H), 6.83 (d, <i>J</i> = 8.5 Hz, 1H), 6.78 (br, 1H), 4.52 (dd, <i>J</i> = 12.0, 6.0 Hz, 1H), 3.92 (d, <i>J</i> = 5.5 Hz, 2H), 3.54 (m, 6H), 3.45 (m, 4H), 3.29 (m, 4H), 3.21 (m, 4H), 2.20 (m, 3H), 2.12 (s, 3H), 1.81–2.00 (m, 6H), 1.22 (d, <i>J</i> = 6.0 Hz, 6H), 1.16 (d, <i>J</i> = 6.5 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 988 (M + H)<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01655" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01655" class="ext-link">10.1021/acs.jmedchem.7b01655</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental methods for biochemical assays, cell culture, cellular assays, and expression proteomics; IC<sub>50</sub> values for biochemical assays and cellular IC<sub>50</sub> curves; dose–response Westerns; shRNA studies for ABCB1; expression proteomics in Kelly cells; cellular IC<sub>50</sub> values for Ba/F3 EML4-ALK cells (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_001.csv">jm7b01655_si_001.csv (2.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf">jm7b01655_si_002.pdf (6.69 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01655" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathanael S. Gray</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5354-7403" title="Orcid link">http://orcid.org/0000-0001-5354-7403</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c38da2b7aba2ada2a6af9c84b1a2ba83a7a5a0aaedaba2b1b5a2b1a7eda6a7b6"><span class="__cf_email__" data-cfemail="145a75607c757a7571784b5366756d547072777d3a7c7566627566703a717061">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chelsea
E. Powell</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7624-1116" title="Orcid link">http://orcid.org/0000-0001-7624-1116</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Gao</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatric Hematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Tan</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine A. Donovan</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Radosław
P. Nowak</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda Loehr</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatric Hematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magda Bahcall</span> - <span class="hlFld-Affiliation affiliation">Lowe Center for Thoracic Oncology, , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric S. Fischer</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pasi A. Jänne</span> - <span class="hlFld-Affiliation affiliation">Lowe Center for Thoracic Oncology, 
    Belfer Center
for Applied Cancer Science, 
    , , and , Dana-Farber
Cancer Institute, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rani E. George</span> - <span class="hlFld-Affiliation affiliation">Department
of Pediatric Hematology and Oncology, Dana-Farber
Cancer Institute and Children’s Hospital Boston, Harvard Medical
School, Boston, Massachusetts 02215, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for this work was received from the National Institutes of Health (NIH): Grant R01 CA136851-08 to P.A.J. and N.S.G.; Grant R01 CA148688 to R.E.G.; Grant R01 CA214608-01 to E.S.F. This work was also supported by NIH Grants 5 T32 GM095450-04 and 2 T32 GM007306-40 (C.E.P.) and a Friends for Life Neuroblastoma Fellowship (Y.G.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABCB1</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily B member 1</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">NB</td><td class="NLM_def"><p class="first last">neuroblastoma</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleoplasmin</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The Anaplastic Lymphoma Kinase in the Pathogenesis of Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+Anaplastic+Lymphoma+Kinase+in+the+Pathogenesis+of+Cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lgyW1BaQ-87HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520the%2520Pathogenesis%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK): Structure, Oncogenic Activation, and Pharmacological Inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29%3A+Structure%2C+Oncogenic+Activation%2C+and+Pharmacological+Inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lh5nLxBODrp1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%253A%2520Structure%252C%2520Oncogenic%2520Activation%252C%2520and%2520Pharmacological%2520Inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms that Underpin EML4-ALK Driven Cancers and Their Response to Targeted Drugs</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-2117-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1007%2Fs00018-015-2117-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26755435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1209-1224&author=R.+Baylissauthor=J.+Choiauthor=D.+A.+Fennellauthor=A.+M.+Fryauthor=M.+W.+Richards&title=Molecular+Mechanisms+that+Underpin+EML4-ALK+Driven+Cancers+and+Their+Response+to+Targeted+Drugs&doi=10.1007%2Fs00018-015-2117-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs</span></div><div class="casAuthors">Bayliss, Richard; Choi, Jene; Fennell, Dean A.; Fry, Andrew M.; Richards, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1209-1224</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A fusion between the EML4 (echinoderm microtubule-assocd. protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit of patients.  However, we have a poor understanding of EML4 and ALK biol. and there are many challenges to devising the optimal strategy for treating EML4-ALK NSCLC patients.  In this review, we describe the biol. of EML4 and ALK, explain the main features of EML4-ALK fusion proteins and outline the therapies that target EML4-ALK.  In particular, we highlight the recent advances in our understanding of the structures of EML proteins, describe the mol. mechanisms of resistance to ALK inhibitors and assess current thinking about combinations of ALK drugs with inhibitors that target other kinases or Hsp90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUKOVGNalV9LVg90H21EOLACvtfcHk0lh5nLxBODrp1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOiuw%253D%253D&md5=9fbba0e0d4c49c4ffdc0dfaef6f19798</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2117-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2117-6%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DD.%2BA.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26atitle%3DMolecular%2520Mechanisms%2520that%2520Underpin%2520EML4-ALK%2520Driven%2520Cancers%2520and%2520Their%2520Response%2520to%2520Targeted%2520Drugs%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D1209%26epage%3D1224%26doi%3D10.1007%2Fs00018-015-2117-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Activating Mutations in ALK Provide a Therapeutic Target in Neuroblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+Mutations+in+ALK+Provide+a+Therapeutic+Target+in+Neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520Mutations%2520in%2520ALK%2520Provide%2520a%2520Therapeutic%2520Target%2520in%2520Neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lgxgOdacdVUgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernersson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase: Signalling in Development and Disease</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+Lymphoma+Kinase%3A+Signalling+in+Development+and+Disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%253A%2520Signalling%2520in%2520Development%2520and%2520Disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the Chromosome 2 Gene Locus Altered by the t(2;5) in Non-Hodgkin’s Lymphoma, Encodes a Novel Neural Receptor Tyrosine Kinase that is Highly Related to Leukocyte Tyrosine Kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+Chromosome+2+Gene+Locus+Altered+by+the+t%282%3B5%29+in+Non-Hodgkin%E2%80%99s+Lymphoma%2C+Encodes+a+Novel+Neural+Receptor+Tyrosine+Kinase+that+is+Highly+Related+to+Leukocyte+Tyrosine+Kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0lgxgOdacdVUgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520Chromosome%25202%2520Gene%2520Locus%2520Altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%252C%2520Encodes%2520a%2520Novel%2520Neural%2520Receptor%2520Tyrosine%2520Kinase%2520that%2520is%2520Highly%2520Related%2520to%2520Leukocyte%2520Tyrosine%2520Kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib Versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1704795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1056%2FNEJMoa1704795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=28586279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=829-838&author=S.+Petersauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=S.+Gadgeelauthor=J.+S.+Ahnauthor=D.-W.+Kimauthor=S.-H.+I.+Ouauthor=M.+P%C3%A9rolauthor=R.+Dziadziuszkoauthor=R.+Rosellauthor=A.+Zeaiterauthor=E.+Mitryauthor=S.+Goldingauthor=B.+Balasauthor=J.+Noeauthor=P.+N.+Morcosauthor=T.+Mok&title=Alectinib+Versus+Crizotinib+in+Untreated+ALK-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1704795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span></div><div class="casAuthors">Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-pos. non-small-cell lung cancer (NSCLC).  We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-pos. NSCLC, including those with asymptomatic CNS disease.  METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-pos. NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily).  The primary end point was investigator assessed progression-free survival.  Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.  RESULTS: During a median follow-up of 17.6 mo (crizotinib) and 18.6 mo (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group.  The rate of investigator- assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-mo event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached.  The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point.  A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001).  A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P = 0.09).  Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).  CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaWsEV8z16LVg90H21EOLACvtfcHk0limHL6dX3ROyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL&md5=cb58ab7eb5b266a3d292eb714a1c8104</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1704795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1704795%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DMitry%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DAlectinib%2520Versus%2520Crizotinib%2520in%2520Untreated%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D829%26epage%3D838%26doi%3D10.1056%2FNEJMoa1704795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr</span></span> <span> </span><span class="NLM_article-title">First-Line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-Rearranged Non-Small-Cell Lung Cancer (ASCEND-4): a Randomised, Open-Label, Phase 3 Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.-C.+Soriaauthor=D.+S.+W.+Tanauthor=R.+Chiariauthor=Y.-L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L.+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.-J.+Yuauthor=M.+Hochmairauthor=A.+B.+Cortotauthor=C.-M.+Tsaiauthor=D.+Moro-Sibilotauthor=R.+G.+Campeloauthor=T.+McCullochauthor=P.+Senauthor=M.+Duganauthor=S.+Pantanoauthor=F.+Branleauthor=C.+Massacesiauthor=G.+de+Castro&title=First-Line+Ceritinib+Versus+Platinum-Based+Chemotherapy+in+Advanced+ALK-Rearranged+Non-Small-Cell+Lung+Cancer+%28ASCEND-4%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0limHL6dX3ROyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DHochmair%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCampelo%26aufirst%3DR.%2BG.%26aulast%3DMcCulloch%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DBranle%26aufirst%3DF.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26atitle%3DFirst-Line%2520Ceritinib%2520Versus%2520Platinum-Based%2520Chemotherapy%2520in%2520Advanced%2520ALK-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ASCEND-4%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessop, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">120ra17</span>– <span class="NLM_lpage">120ra17</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17-120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+Acquired+Crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26epage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, C.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1177/1060028014553619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1177%2F1060028014553619" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=107-112&author=M.+R.+Cooperauthor=H.+Chimauthor=H.+Chanauthor=C.+Durand&title=Ceritinib%3A+A+New+Tyrosine+Kinase+Inhibitor+for+Non-Small-Cell+Lung+Cancer&doi=10.1177%2F1060028014553619"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1060028014553619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028014553619%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DChim%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDurand%26aufirst%3DC.%26atitle%3DCeritinib%253A%2520A%2520New%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2015%26volume%3D49%26spage%3D107%26epage%3D112%26doi%3D10.1177%2F1060028014553619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">ALK Inhibitors in Non-Small Cell Lung Cancer: the Latest Evidence and Developments</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1177/1758834015617355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1177%2F1758834015617355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26753004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=32-47&author=I.+Sullivanauthor=D.+Planchard&title=ALK+Inhibitors+in+Non-Small+Cell+Lung+Cancer%3A+the+Latest+Evidence+and+Developments&doi=10.1177%2F1758834015617355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: the latest evidence and developments</span></div><div class="casAuthors">Sullivan, Ivana; Planchard, David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small mol. inhibitor of ALK, ROS1 and MET.  Unfortunately, the disease progressed within the first 12 mo in most of the patients because of the development of crizotinib resistance in the majority of patients and the emergence of acquired resistance mutations in most of them.  Many of them had been reported even before its approval leading to the rapid development of second-generation ALK inhibitors for crizotinibresistant NSCLC.  In the last few years, novel potent ALK inhibitors with promising results and a good toxicity profile have become available: ceritinib (LDK378), alectinib (RG7853/ AF-802/RO5424802/CH5424802), brigatinib (AP26113), entrectinib (RXDX-101, NMS-E628), PF-06463922, ASP3026, TSR-011, X-376/X-396 and CEP-28122/CEP-37440.  Moreover, HSP90 (90 kDa heat shock protein) inhibitors have demonstrated clin. activity in patients with ALK+ NSCLC.  This review focuses on the mol. and clin. properties of this new generation of ALK inhibitors under development in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmT62DyyrILVg90H21EOLACvtfcHk0likBa01cLl9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE&md5=9266542af3ea2ad9aadde47361105372</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1758834015617355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015617355%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520the%2520Latest%2520Evidence%2520and%2520Developments%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D8%26spage%3D32%26epage%3D47%26doi%3D10.1177%2F1758834015617355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span> <span> </span><span class="NLM_article-title">Expanding the Portfolio of Anti-ALK Weapons</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2014.07.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.3978%2Fj.issn.2218-6751.2014.07.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25806340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=5-7&author=L.+Mologni&title=Expanding+the+Portfolio+of+Anti-ALK+Weapons&doi=10.3978%2Fj.issn.2218-6751.2014.07.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the portfolio of anti-ALK weapons</span></div><div class="casAuthors">Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-7</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the onset of several malignancies.  In particular, ALK is the driving oncogenic lesion in a small but significant fraction of non-small cell lung cancer (NSCLC) patients.  ALK+ NSCLCs can be treated with the dual ALK/MET inhibitor crizotinib, with better outcome compared to std. chemotherapy.  However, relapses frequently occur, due to various mechanisms, limiting overall efficacy of the treatment.  Point mutations within the ALK catalytic domain or ALK gene amplification account for approx. 30-40% of crizotinib-resistant cases, suggesting that the diseases still relies on ALK activity and that more potent inhibitors could be useful in this setting.  Ceritinib is a novel selective ALK inhibitor with preclin. activity against crizotinib-resistant ALK mutants.  A recent article in the New England Journal of Medicine reports on clin. evaluation of ceritinib.  Response rate and progression-free survival (PFS) were comparable to crizotinib, but most importantly, crizotinib-resistant patients were successfully treated, with efficacy similar to crizotinib-na.ovrddot.ive patients.  The study extends the array of available anti-ALK drugs.  Based on these data, ceritinib was approved by FDA in Apr. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3jQk-1XeaLVg90H21EOLACvtfcHk0likBa01cLl9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7vJ&md5=f46c7192a6c48ba162d53beda5f6c23a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.07.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.07.02%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DExpanding%2520the%2520Portfolio%2520of%2520Anti-ALK%2520Weapons%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D5%26epage%3D7%26doi%3D10.3978%2Fj.issn.2218-6751.2014.07.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5686</span>– <span class="NLM_lpage">5696</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+Novel+ALK+Mutations+Mediate+Acquired+Resistance+to+the+Next-Generation+ALK+Inhibitor+Alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0likBa01cLl9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520Novel%2520ALK%2520Mutations%2520Mediate%2520Acquired%2520Resistance%2520to%2520the%2520Next-Generation%2520ALK%2520Inhibitor%2520Alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span> <span> </span><span class="NLM_article-title">The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions</span>. <i>Targeted Oncology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1007/s11523-017-0526-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1007%2Fs11523-017-0526-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=709-718&author=A.+Qinauthor=S.+Gadgeel&title=The+Current+Landscape+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+in+Non-Small+Cell+Lung+Cancer%3A+Emerging+Treatment+Paradigms+and+Future+Directions&doi=10.1007%2Fs11523-017-0526-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0526-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0526-1%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DA.%26aulast%3DGadgeel%26aufirst%3DS.%26atitle%3DThe%2520Current%2520Landscape%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Emerging%2520Treatment%2520Paradigms%2520and%2520Future%2520Directions%26jtitle%3DTargeted%2520Oncology%26date%3D2017%26volume%3D12%26spage%3D709%26epage%3D718%26doi%3D10.1007%2Fs11523-017-0526-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+Crizotinib+by+the+Lorlatinib+ALK+Resistance+Mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0lgAqOxThGAfoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520Crizotinib%2520by%2520the%2520Lorlatinib%2520ALK%2520Resistance%2520Mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+Conjugation+as+a+Strategy+for+in+Vivo+Target+Protein+Degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0lhNpBfeY7Ms_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520Conjugation%2520as%2520a%2520Strategy%2520for%2520in%2520Vivo%2520Target%2520Protein%2520Degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span>. <i>Angew. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1002/ange.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1002%2Fange.201507634" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=818-821&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+Design+for+the+Degradation+of+Oncogenic+BCR-ABL&doi=10.1002%2Fange.201507634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fange.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520Design%2520for%2520the%2520Degradation%2520of%2520Oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%26date%3D2016%26volume%3D128%26spage%3D818%26epage%3D821%26doi%3D10.1002%2Fange.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span>. <i>Cell Chemical Biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.-T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.-H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+Chemoproteomic+Approach+to+Query+the+Degradable+Kinome+Using+a+Multi-kinase+Degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.-T.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.-H.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520Chemoproteomic%2520Approach%2520to%2520Query%2520the%2520Degradable%2520Kinome%2520Using%2520a%2520Multi-kinase%2520Degrader%26jtitle%3DCell%2520Chemical%2520Biology%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhNpBfeY7Ms_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.%0AH.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-+N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-+N4-%282-%28isopropylsulfonyl%29phenyl%29+pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-%2520N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-%2520N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529%2520pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2140</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-10-2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=21415216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2140-2148&author=K.+Takezawaauthor=I.+Okamotoauthor=K.+Nishioauthor=P.+A.+Janneauthor=K.+Nakagawa&title=Role+of+ERK-BIM+and+STAT3-Survivin+Signaling+Pathways+in+ALK+Inhibitor-Induced+Apoptosis+in+EML4-ALK-Positive+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer</span></div><div class="casAuthors">Takezawa, Ken; Okamoto, Isamu; Nishio, Kazuto; Jaenne, Pasi A.; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2140-2148</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE:EML4-ALK (echinoderm microtubule-assocd. protein-like 4 anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer.  The purpose of the present study was to characterize the mechanism of malignant transformation by EML4-ALK.  Exptl. Design: We established NIH 3T3 cells that stably express variant 1 or 3 of EML4-ALK and examd. the signaling mols. that function downstream of EML4-ALK.  RESULTS: Forced expression of EML4-ALK induced marked activation of extracellular signal-regulated kinase (ERK) and STAT3, but not that of AKT.  Inhibition of ERK or STAT3 signaling resulted in substantial attenuation of the proliferation of cells expressing either variant of EML4-ALK, suggesting that these signaling pathways function downstream of EML4-ALK in lung cancer cells.  The specific ALK inhibitor TAE684 induced apoptosis that was accompanied both by upregulation of BIM, a proapoptotic member of the Bcl-2 family, and by downregulation of survivin, a member of the inhibitor of apoptosis protein (IAP) family, in EML4-ALK-expressing NIH 3T3 cells as well as in H3122 human lung cancer cells harboring endogenous EML4-ALK.  Depletion of BIM and overexpression of survivin each inhibited TAE684-induced apoptosis, suggesting that both upregulation of BIM and downregulation of survivin contribute to TAE684-induced apoptosis in EML4-ALK-pos. lung cancer cells.  Furthermore, BIM and survivin expression was found to be independently regulated by ERK and STAT3 signaling pathways, resp.  CONCLUSIONS: ALK inhibitor-induced apoptosis is mediated both by BIM upregulation resulting from inhibition of ERK signaling as well as by survivin downregulation resulting from inhibition of STAT3 signaling in EML4-ALK-pos. lung cancer cells.  Clin Cancer Res; 17(8); 2140-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7tzBYeSL6fbVg90H21EOLACvtfcHk0liVKYV7urnJeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgsL0%253D&md5=218323843787c0a53794d661533d730f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2798%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DRole%2520of%2520ERK-BIM%2520and%2520STAT3-Survivin%2520Signaling%2520Pathways%2520in%2520ALK%2520Inhibitor-Induced%2520Apoptosis%2520in%2520EML4-ALK-Positive%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2140%26epage%3D2148%26doi%3D10.1158%2F1078-0432.CCR-10-2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0liVKYV7urnJeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squillace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadworny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miret, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5538</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+Potent+ALK+Inhibitor+Brigatinib+%28AP26113%29+Overcomes+Mechanisms+of+Resistance+to+First-+and+Second-Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0ligfglE_O5mOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Potent%2520ALK%2520Inhibitor%2520Brigatinib%2520%2528AP26113%2529%2520Overcomes%2520Mechanisms%2520of%2520Resistance%2520to%2520First-%2520and%2520Second-Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span>; <span class="NLM_string-name">Huynh, T.</span>; <span class="NLM_string-name">Truong, A. M.</span>; <span class="NLM_string-name">Haber, M.</span>; <span class="NLM_string-name">Norris, M. D.</span></span> <i>ABC Transporters and Neuroblastoma</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier Inc.</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">125</span>, pp  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">170</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fbs.acr.2014.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=139-170&author=D.+M.+T.+Yu&author=T.+Huynh&author=A.+M.+Truong&author=M.+Haber&author=M.+D.+Norris&title=ABC+Transporters+and+Neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2014.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252Fbs.acr.2014.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26btitle%3DABC%2520Transporters%2520and%2520Neuroblastoma%26pub%3DElsevier%2520Inc%26date%3D2015%26volume%3D125%26spage%3D139%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chima, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunjan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretswell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangerfield, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span> <span> </span><span class="NLM_article-title">Reversal of P-Glycoprotein Mediated Multidrug Resistance by Novel Anthranilamide Derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00030-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2FS0960-894X%2899%2900030-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10098671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVylsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=595-600&author=M.+Roeauthor=A.+Folkesauthor=P.+Ashworthauthor=J.+Brumwellauthor=L.+Chimaauthor=S.+Hunjanauthor=I.+Pretswellauthor=W.+Dangerfieldauthor=H.+Ryderauthor=P.+Charlton&title=Reversal+of+P-Glycoprotein+Mediated+Multidrug+Resistance+by+Novel+Anthranilamide+Derivatives&doi=10.1016%2FS0960-894X%2899%2900030-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives</span></div><div class="casAuthors">Roe, Michael; Folkes, Adrian; Ashworth, Philip; Brumwell, Julie; Chima, Lal; Hunjan, Sukhjit; Pretswell, Ian; Dangerfield, Wendy; Ryder, Hamish; Charlton, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-600</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">We have synthesized and evaluated a series of anthranilamide based modulators of P-glycoprotein.  These studies have identified XR9576, a potent inhibitor of P-glycoprotein in vitro and in vivo.  The general synthesis and the SAR of these compds. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQO2OdePDQrVg90H21EOLACvtfcHk0ligfglE_O5mOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVylsrs%253D&md5=d1e096ea9c3a30d3574fbe9b92c657cb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900030-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900030-X%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DM.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DP.%26aulast%3DBrumwell%26aufirst%3DJ.%26aulast%3DChima%26aufirst%3DL.%26aulast%3DHunjan%26aufirst%3DS.%26aulast%3DPretswell%26aufirst%3DI.%26aulast%3DDangerfield%26aufirst%3DW.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DCharlton%26aufirst%3DP.%26atitle%3DReversal%2520of%2520P-Glycoprotein%2520Mediated%2520Multidrug%2520Resistance%2520by%2520Novel%2520Anthranilamide%2520Derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D595%26epage%3D600%26doi%3D10.1016%2FS0960-894X%2899%2900030-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Cross-Talk Between the Ubiquitin-Proteasome and Autophagy-Lysosome Systems</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2009.12.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.febslet.2009.12.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=20040365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs12msro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=1393-1398&author=V.+I.+Korolchukauthor=F.+M.+Menziesauthor=D.+C.+Rubinsztein&title=Mechanisms+of+Cross-Talk+Between+the+Ubiquitin-Proteasome+and+Autophagy-Lysosome+Systems&doi=10.1016%2Fj.febslet.2009.12.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems</span></div><div class="casAuthors">Korolchuk, Viktor I.; Menzies, Fiona M.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) and macroautophagy (hereafter called autophagy) were, for a long time, regarded as independent degradative pathways with few or no points of interaction.  This view started to change recently, in the light of findings that have suggested that ubiquitination can target substrates for degrdn. via both pathways.  Moreover, perturbations in the flux through either pathway have been reported to affect the activity of the other system, and a no. of mechanisms have been proposed to rationalize the link between the UPS and autophagy.  Here, the authors critically review these findings and outline some outstanding issues that still await clarification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreMYT4SAb8VLVg90H21EOLACvtfcHk0lh0VR69vl-WCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs12msro%253D&md5=e95569a7bbf5978a284862669282e1db</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2009.12.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2009.12.047%26sid%3Dliteratum%253Aachs%26aulast%3DKorolchuk%26aufirst%3DV.%2BI.%26aulast%3DMenzies%26aufirst%3DF.%2BM.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DMechanisms%2520of%2520Cross-Talk%2520Between%2520the%2520Ubiquitin-Proteasome%2520and%2520Autophagy-Lysosome%2520Systems%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D1393%26epage%3D1398%26doi%3D10.1016%2Fj.febslet.2009.12.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.ccr.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25065853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=207-221&author=H.-J.+Leeauthor=G.+Zhuangauthor=Y.+Caoauthor=P.+Duauthor=H.-J.+Kimauthor=J.+Settleman&title=Drug+Resistance+via+Feedback+Activation+of+Stat3+in+Oncogene-Addicted+Cancer+Cells&doi=10.1016%2Fj.ccr.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span></div><div class="casAuthors">Lee, Ho-June; Zhuang, Guanglei; Cao, Yi; Du, Pan; Kim, Hyo-Jin; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells.  We found that many drug-treated "oncogene-addicted" cancer cells engage a pos. feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response.  This was obsd. in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS.  Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacol. inhibition of MEK together with JAK and FGFR enhanced tumor regression.  These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9wv2-E6LTCLVg90H21EOLACvtfcHk0lh0VR69vl-WCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I&md5=d180509b8b5a63331e8edbd0d2bf9a63</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-J.%26aulast%3DZhuang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DDrug%2520Resistance%2520via%2520Feedback%2520Activation%2520of%2520Stat3%2520in%2520Oncogene-Addicted%2520Cancer%2520Cells%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fj.ccr.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lh0VR69vl-WCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+Ubiquitin+Ligase+Cereblon+to+Efficiently+Target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0lj6p-ddM-MSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520Ubiquitin%2520Ligase%2520Cereblon%2520to%2520Efficiently%2520Target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 73 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu, <span class="NLM_string-name hlFld-ContribAuthor">Shengtao Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9120-9140. <a href="https://doi.org/10.1021/acs.jmedchem.1c00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00270%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlectinib-Based%252BPROTACs%252Bas%252BNovel%252BPotent%252BDegraders%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DXie%26aufirst%3DShaowen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11022021%26date%3D28062021%26volume%3D64%26issue%3D13%26spage%3D9120%26epage%3D9140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaowei Ren, Ning Sun, Haixia Liu, Ying Kong, Renhong Sun, Xing Qiu, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou, Hui Zhong, Qianqian Yin, Xiaoling Song, Xiaobao Yang, <span class="NLM_string-name hlFld-ContribAuthor">Biao Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9152-9165. <a href="https://doi.org/10.1021/acs.jmedchem.1c00373" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00373%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBrigatinib%252BDegrader%252BSIAIS164018%252Bwith%252BDestroying%252BMetastasis-Related%252BOncoproteins%252Band%252Ba%252BReshuffling%252BKinome%252BProfile%26aulast%3DRen%26aufirst%3DChaowei%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D17062021%26volume%3D64%26issue%3D13%26spage%3D9152%26epage%3D9165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nan Bai, Sven A. Miller, Grigorii V. Andrianov, Max Yates, Palani Kirubakaran, <span class="NLM_string-name hlFld-ContribAuthor">John Karanicolas</span>. </span><span class="cited-content_cbyCitation_article-title">Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (3)
                                     , 1368-1382. <a href="https://doi.org/10.1021/acs.jcim.0c01451" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01451%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DRationalizing%252BPROTAC-Mediated%252BTernary%252BComplex%252BFormation%252BUsing%252BRosetta%26aulast%3DBai%26aufirst%3DNan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D17122020%26date%3D24022021%26volume%3D61%26issue%3D3%26spage%3D1368%26epage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Lu, <span class="NLM_string-name hlFld-ContribAuthor">Haiying Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14382-14403. <a href="https://doi.org/10.1021/acs.jmedchem.0c01248" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01248%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecular%252BInhibitors%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%26aulast%3DLu%26aufirst%3DYang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17072020%26date%3D15102020%26volume%3D63%26issue%3D23%26spage%3D14382%26epage%3D14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liqun Chen, Yanke Chen, Chunyan Zhang, Bingyang Jiao, Sheng Liang, Qiong Tan, Hongyu Chai, Weihua Yu, Yongzheng Qian, Hui Yang, Wuyi Yao, Jianguo Yu, Ying Luo, Michael Plewe, Jialiang Wang, Xiao-Ran Han, <span class="NLM_string-name hlFld-ContribAuthor">Jing Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14562-14575. <a href="https://doi.org/10.1021/acs.jmedchem.0c01342" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01342%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BFirst-In-Class%252BPotent%252Band%252BSelective%252BTropomyosin%252BReceptor%252BKinase%252BDegraders%26aulast%3DChen%26aufirst%3DLiqun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07082020%26date%3D15102020%26volume%3D63%26issue%3D23%26spage%3D14562%26epage%3D14575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingliang Wang, Jianfeng Lu, Mi Wang, Chao-Yie Yang, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (14)
                                     , 7510-7528. <a href="https://doi.org/10.1021/acs.jmedchem.0c00471" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00471%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSHP2-D26%252Bas%252Ba%252BFirst%25252C%252BPotent%25252C%252Band%252BEffective%252BPROTAC%252BDegrader%252Bof%252BSHP2%252BProtein%26aulast%3DWang%26aufirst%3DMingliang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20032020%26date%3D21052020%26volume%3D63%26issue%3D14%26spage%3D7510%26epage%3D7528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bingqi Tong, Jessica N. Spradlin, Luiz F. T. Novaes, Erika Zhang, Xirui Hu, Malte Moeller, Scott M. Brittain, Lynn M. McGregor, Jeffrey M. McKenna, John A. Tallarico, Markus Schirle, Thomas J. Maimone, <span class="NLM_string-name hlFld-ContribAuthor">Daniel K. Nomura</span>. </span><span class="cited-content_cbyCitation_article-title">A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2020,</strong> <em>15 </em>
                                    (7)
                                     , 1788-1794. <a href="https://doi.org/10.1021/acschembio.0c00348" title="DOI URL">https://doi.org/10.1021/acschembio.0c00348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00348%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DA%252BNimbolide-Based%252BKinase%252BDegrader%252BPreferentially%252BDegrades%252BOncogenic%252BBCR-ABL%26aulast%3DTong%26aufirst%3DBingqi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05052020%26date%3D22062020%26date%3D25062020%26date%3D22062020%26volume%3D15%26issue%3D7%26spage%3D1788%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu-Hui Jin, Meng-Chen Lu, Yan Wang, Wen-Xin Shan, Xuan-Yu Wang, Qi-Dong You, <span class="NLM_string-name hlFld-ContribAuthor">Zheng-Yu Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4644-4654. <a href="https://doi.org/10.1021/acs.jmedchem.9b02058" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02058%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAzo-PROTAC%25253A%252BNovel%252BLight-Controlled%252BSmall-Molecule%252BTool%252Bfor%252BProtein%252BKnockdown%26aulast%3DJin%26aufirst%3DYu-Hui%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D11122019%26date%3D19032020%26date%3D10032020%26volume%3D63%26issue%3D9%26spage%3D4644%26epage%3D4654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Han, Lijie Zhao, Weiguo Xiang, Chong Qin, Bukeyan Miao, Tianfeng Xu, Mi Wang, Chao-Yie Yang, Krishnapriya Chinnaswamy, Jeanne Stuckey, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11218-11231. <a href="https://doi.org/10.1021/acs.jmedchem.9b01393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BHighly%252BPotent%252Band%252BEfficient%252BPROTAC%252BDegraders%252Bof%252BAndrogen%252BReceptor%252B%252528AR%252529%252Bby%252BEmploying%252BWeak%252BBinding%252BAffinity%252BVHL%252BE3%252BLigase%252BLigands%26aulast%3DHan%26aufirst%3DXin%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22082019%26date%3D05122019%26volume%3D62%26issue%3D24%26spage%3D11218%26epage%3D11231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nobumichi Ohoka, Genichiro Tsuji, Takuji Shoda, Takuma Fujisato, Masaaki Kurihara, Yosuke Demizu, <span class="NLM_string-name hlFld-ContribAuthor">Mikihiko Naito</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (12)
                                     , 2822-2832. <a href="https://doi.org/10.1021/acschembio.9b00704" title="DOI URL">https://doi.org/10.1021/acschembio.9b00704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00704%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDevelopment%252Bof%252BSmall%252BMolecule%252BChimeras%252BThat%252BRecruit%252BAhR%252BE3%252BLigase%252Bto%252BTarget%252BProteins%26aulast%3DOhoka%26aufirst%3DNobumichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03092019%26date%3D02102019%26date%3D16102019%26date%3D03102019%26volume%3D14%26issue%3D12%26spage%3D2822%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrick Pfaff, Kusal T. G. Samarasinghe, Craig M. Crews, <span class="NLM_string-name hlFld-ContribAuthor">Erick M. Carreira</span>. </span><span class="cited-content_cbyCitation_article-title">Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2019,</strong> <em>5 </em>
                                    (10)
                                     , 1682-1690. <a href="https://doi.org/10.1021/acscentsci.9b00713" title="DOI URL">https://doi.org/10.1021/acscentsci.9b00713</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.9b00713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.9b00713%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DReversible%252BSpatiotemporal%252BControl%252Bof%252BInduced%252BProtein%252BDegradation%252Bby%252BBistable%252BPhotoPROTACs%26aulast%3DPfaff%26aufirst%3DPatrick%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17072019%26date%3D17092019%26volume%3D5%26issue%3D10%26spage%3D1682%26epage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xing Qiu, Ning Sun, Ying Kong, Yan Li, Xiaobao Yang, <span class="NLM_string-name hlFld-ContribAuthor">Biao Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (10)
                                     , 3838-3841. <a href="https://doi.org/10.1021/acs.orglett.9b01326" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01326%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DChemoselective%252BSynthesis%252Bof%252BLenalidomide-Based%252BPROTAC%252BLibrary%252BUsing%252BAlkylation%252BReaction%26aulast%3DQiu%26aufirst%3DXing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16042019%26date%3D08052019%26volume%3D21%26issue%3D10%26spage%3D3838%26epage%3D3841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Johannes Popow, Heribert Arnhof, Gerd Bader, Helmut Berger, Alessio Ciulli, David Covini, Christian Dank, Teresa Gmaschitz, Peter Greb, Jale Karolyi-Özguer, Manfred Koegl, Darryl B. McConnell, Mark Pearson, Maria Rieger, Joerg Rinnenthal, Vanessa Roessler, Andreas Schrenk, Markus Spina, Steffen Steurer, Nicole Trainor, Elisabeth Traxler, Corinna Wieshofer, Andreas Zoephel, <span class="NLM_string-name hlFld-ContribAuthor">Peter Ettmayer</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2508-2520. <a href="https://doi.org/10.1021/acs.jmedchem.8b01826" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01826</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01826%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BPTK2%252BProteolysis%252BTargeting%252BChimeras%252Bto%252BProbe%252BFocal%252BAdhesion%252BKinase%252BScaffolding%252BFunctions%26aulast%3DPopow%26aufirst%3DJohannes%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D22112018%26date%3D22022019%26date%3D09022019%26volume%3D62%26issue%3D5%26spage%3D2508%26epage%3D2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Han, Chao Wang, Chong Qin, Weiguo Xiang, Ester Fernandez-Salas, Chao-Yie Yang, Mi Wang, Lijie Zhao, Tianfeng Xu, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 941-964. <a href="https://doi.org/10.1021/acs.jmedchem.8b01631" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BARD-69%252Bas%252Ba%252BHighly%252BPotent%252BProteolysis%252BTargeting%252BChimera%252B%252528PROTAC%252529%252BDegrader%252Bof%252BAndrogen%252BReceptor%252B%252528AR%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BProstate%252BCancer%26aulast%3DHan%26aufirst%3DXin%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21102018%26date%3D10012019%26volume%3D62%26issue%3D2%26spage%3D941%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenzhen  Li</span>, <span class="hlFld-ContribAuthor ">Siyue  Ma</span>, <span class="hlFld-ContribAuthor ">Xingye  Yang</span>, <span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Dong  Liang</span>, <span class="hlFld-ContribAuthor ">Gaopan  Dong</span>, <span class="hlFld-ContribAuthor ">Lupei  Du</span>, <span class="hlFld-ContribAuthor ">Zhenghua  Lv</span>, <span class="hlFld-ContribAuthor ">Minyong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113608. <a href="https://doi.org/10.1016/j.ejmech.2021.113608" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113608%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bphotocontrolled%252BBRD4%252BPROTACs%252Bfor%252Btongue%252Bsquamous%252Bcell%252Bcarcinoma%252B%252528TSCC%252529%26aulast%3DLi%26aufirst%3DZhenzhen%26date%3D2021%26volume%3D222%26spage%3D113608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Yunhua  Peng</span>, <span class="hlFld-ContribAuthor ">Wenyi  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Light-Controllable PROTACs for Temporospatial Control of Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.678077" title="DOI URL">https://doi.org/10.3389/fcell.2021.678077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.678077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.678077%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DLight-Controllable%252BPROTACs%252Bfor%252BTemporospatial%252BControl%252Bof%252BProtein%252BDegradation%26aulast%3DLiu%26aufirst%3DJing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleša  Bricelj</span>, <span class="hlFld-ContribAuthor ">Christian  Steinebach</span>, <span class="hlFld-ContribAuthor ">Robert  Kuchta</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Izidor  Sosič</span>. </span><span class="cited-content_cbyCitation_article-title">E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.707317" title="DOI URL">https://doi.org/10.3389/fchem.2021.707317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.707317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.707317%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DE3%252BLigase%252BLigands%252Bin%252BSuccessful%252BPROTACs%25253A%252BAn%252BOverview%252Bof%252BSyntheses%252Band%252BLinker%252BAttachment%252BPoints%26aulast%3DBricelj%26aufirst%3DAle%25C5%25A1a%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shusuke  Tomoshige</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>41 </em>, 116221. <a href="https://doi.org/10.1016/j.bmc.2021.116221" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116221%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIn%252Bvivo%252Bsynthetic%252Bchemistry%252Bof%252Bproteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%26aulast%3DTomoshige%26aufirst%3DShusuke%26date%3D2021%26volume%3D41%26spage%3D116221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah  Kiely-Collins</span>, <span class="hlFld-ContribAuthor ">Georg E.  Winter</span>, <span class="hlFld-ContribAuthor ">Gonçalo J.L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">The role of reversible and irreversible covalent chemistry in targeted protein degradation. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (7)
                                     , 952-968. <a href="https://doi.org/10.1016/j.chembiol.2021.03.005" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DThe%252Brole%252Bof%252Breversible%252Band%252Birreversible%252Bcovalent%252Bchemistry%252Bin%252Btargeted%252Bprotein%252Bdegradation%26aulast%3DKiely-Collins%26aufirst%3DHannah%26date%3D2021%26volume%3D28%26issue%3D7%26spage%3D952%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kusal T.G.  Samarasinghe</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted protein degradation: A promise for undruggable proteins. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (7)
                                     , 934-951. <a href="https://doi.org/10.1016/j.chembiol.2021.04.011" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DTargeted%252Bprotein%252Bdegradation%25253A%252BA%252Bpromise%252Bfor%252Bundruggable%252Bproteins%26aulast%3DSamarasinghe%26aufirst%3DKusal%2BT.G.%26date%3D2021%26volume%3D28%26issue%3D7%26spage%3D934%26epage%3D951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoling  Song</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Qu</span>, <span class="hlFld-ContribAuthor ">Linsong  Yang</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras. </span><span class="cited-content_cbyCitation_journal-name">MedComm</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1002/mco2.42" title="DOI URL">https://doi.org/10.1002/mco2.42</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mco2.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmco2.42%26sid%3Dliteratum%253Aachs%26jtitle%3DMedComm%26atitle%3DTwo%252Bnovel%252Bstrategies%252Bto%252Bovercome%252Bthe%252Bresistance%252Bto%252BALK%252Btyrosine%252Bkinase%252Binhibitor%252Bdrugs%25253A%252BMacrocyclic%252Binhibitors%252Band%252Bproteolysis%2525E2%252580%252590targeting%252Bchimeras%26aulast%3DSong%26aufirst%3DXiaoling%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangbo  Yang</span>, <span class="hlFld-ContribAuthor ">Zhijia  Wang</span>, <span class="hlFld-ContribAuthor ">Yuan  Pei</span>, <span class="hlFld-ContribAuthor ">Ning  Song</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Bo  Feng</span>, <span class="hlFld-ContribAuthor ">Hanlin  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Qiu</span>, <span class="hlFld-ContribAuthor ">Huijin  Feng</span>, <span class="hlFld-ContribAuthor ">Yaxi  Yang</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113341. <a href="https://doi.org/10.1016/j.ejmech.2021.113341" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113341%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthalidomide-based%252BPROTAC%252Bsmall%252Bmolecules%252Bas%252Bthe%252Bhighly%252Befficient%252BSHP2%252Bdegraders%26aulast%3DYang%26aufirst%3DXiangbo%26date%3D2021%26volume%3D218%26spage%3D113341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaowei  Ren</span>, <span class="hlFld-ContribAuthor ">Ning  Sun</span>, <span class="hlFld-ContribAuthor ">Ying  Kong</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Qu</span>, <span class="hlFld-ContribAuthor ">Haixia  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Song</span>, <span class="hlFld-ContribAuthor ">Xiaobao  Yang</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113335. <a href="https://doi.org/10.1016/j.ejmech.2021.113335" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113335%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdiscovery%252Bof%252BSIAIS001%252Bas%252Ban%252Boral%252Bbioavailability%252BALK%252Bdegrader%252Bconstructed%252Bfrom%252BAlectinib%26aulast%3DRen%26aufirst%3DChaowei%26date%3D2021%26volume%3D217%26spage%3D113335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlotta  Cecchini</span>, <span class="hlFld-ContribAuthor ">Sara  Pannilunghi</span>, <span class="hlFld-ContribAuthor ">Sébastien  Tardy</span>, <span class="hlFld-ContribAuthor ">Leonardo  Scapozza</span>. </span><span class="cited-content_cbyCitation_article-title">From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.672267" title="DOI URL">https://doi.org/10.3389/fchem.2021.672267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.672267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.672267%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DFrom%252BConception%252Bto%252BDevelopment%25253A%252BInvestigating%252BPROTACs%252BFeatures%252Bfor%252BImproved%252BCell%252BPermeability%252Band%252BSuccessful%252BProtein%252BDegradation%26aulast%3DCecchini%26aufirst%3DCarlotta%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tae Gwang  Yun</span>, <span class="hlFld-ContribAuthor ">Ji-Soo  Jang</span>, <span class="hlFld-ContribAuthor ">Jun Young  Cheong</span>, <span class="hlFld-ContribAuthor ">Il-Doo  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Organism epidermis/plant-root inspired ultra-stable supercapacitor for large-scale wearable energy storage applications. </span><span class="cited-content_cbyCitation_journal-name">Nano Energy</span><span> <strong>2021,</strong> <em>82 </em>, 105776. <a href="https://doi.org/10.1016/j.nanoen.2021.105776" title="DOI URL">https://doi.org/10.1016/j.nanoen.2021.105776</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nanoen.2021.105776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nanoen.2021.105776%26sid%3Dliteratum%253Aachs%26jtitle%3DNano%2520Energy%26atitle%3DOrganism%252Bepidermis%25252Fplant-root%252Binspired%252Bultra-stable%252Bsupercapacitor%252Bfor%252Blarge-scale%252Bwearable%252Benergy%252Bstorage%252Bapplications%26aulast%3DYun%26aufirst%3DTae%2BGwang%26date%3D2021%26volume%3D82%26spage%3D105776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Target Validation Using PROTACs: Applying the Four Pillars Framework. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2021,</strong> <em>26 </em>
                                    (4)
                                     , 474-483. <a href="https://doi.org/10.1177/2472555220979584" title="DOI URL">https://doi.org/10.1177/2472555220979584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220979584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220979584%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DTarget%252BValidation%252BUsing%252BPROTACs%25253A%252BApplying%252Bthe%252BFour%252BPillars%252BFramework%26aulast%3DNowak%26aufirst%3DRados%25C5%2582aw%2BP.%26date%3D2021%26date%3D2020%26volume%3D26%26issue%3D4%26spage%3D474%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yvonne A.  Nagel</span>, <span class="hlFld-ContribAuthor ">Adrian  Britschgi</span>, <span class="hlFld-ContribAuthor ">Antonio  Ricci</span>. </span><span class="cited-content_cbyCitation_article-title">From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 47-85. <a href="https://doi.org/10.1002/9783527826872.ch2" title="DOI URL">https://doi.org/10.1002/9783527826872.ch2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527826872.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527826872.ch2%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%252BDegraders%252Bto%252BMolecular%252BGlues%25253A%252BNew%252BWays%252Bof%252BBreaking%252BDown%252BDisease%2525E2%252580%252590Associated%252BProteins%26aulast%3DNagel%26aufirst%3DYvonne%2BA.%26date%3D2021%26date%3D2021%26spage%3D47%26epage%3D85%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2021%26date%3D2021%26volume%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaohe  Yang</span>, <span class="hlFld-ContribAuthor ">Yali  Wang</span>, <span class="hlFld-ContribAuthor ">Yueying  Yang</span>, <span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Lixia  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting SHP2 as a therapeutic strategy for inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113264. <a href="https://doi.org/10.1016/j.ejmech.2021.113264" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113264%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BSHP2%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Binflammatory%252Bdiseases%26aulast%3DLiu%26aufirst%3DYang%26date%3D2021%26volume%3D214%26spage%3D113264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shusuke  Tomoshige</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (7)
                                     , 3386-3394. <a href="https://doi.org/10.1002/ange.202004746" title="DOI URL">https://doi.org/10.1002/ange.202004746</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202004746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202004746%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DPROTACs%252Band%252BOther%252BChemical%252BProtein%252BDegradation%252BTechnologies%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurodegenerative%252BDisorders%26aulast%3DTomoshige%26aufirst%3DShusuke%26date%3D2021%26date%3D2020%26volume%3D133%26issue%3D7%26spage%3D3386%26epage%3D3394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shusuke  Tomoshige</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (7)
                                     , 3346-3354. <a href="https://doi.org/10.1002/anie.202004746" title="DOI URL">https://doi.org/10.1002/anie.202004746</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202004746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202004746%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DPROTACs%252Band%252BOther%252BChemical%252BProtein%252BDegradation%252BTechnologies%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurodegenerative%252BDisorders%26aulast%3DTomoshige%26aufirst%3DShusuke%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D7%26spage%3D3346%26epage%3D3354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoyi  Yan</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhong</span>, <span class="hlFld-ContribAuthor ">Lin  Yue</span>, <span class="hlFld-ContribAuthor ">Chunlan  Pu</span>, <span class="hlFld-ContribAuthor ">Huifang  Shan</span>, <span class="hlFld-ContribAuthor ">Suke  Lan</span>, <span class="hlFld-ContribAuthor ">Meng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueyan  Hou</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a PROTAC targeting ALK with in vivo activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113150. <a href="https://doi.org/10.1016/j.ejmech.2020.113150" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113150%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPROTAC%252Btargeting%252BALK%252Bwith%252Bin%2525C2%2525A0vivo%252Bactivity%26aulast%3DYan%26aufirst%3DGuoyi%26date%3D2021%26volume%3D212%26spage%3D113150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinrui  Yang</span>, <span class="hlFld-ContribAuthor ">He  Yin</span>, <span class="hlFld-ContribAuthor ">Richard D.  Kim</span>, <span class="hlFld-ContribAuthor ">Jason B.  Fleming</span>, <span class="hlFld-ContribAuthor ">Hao  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (1)
                                     , 1-12. <a href="https://doi.org/10.1007/s11523-020-00782-2" title="DOI URL">https://doi.org/10.1007/s11523-020-00782-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-020-00782-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-020-00782-2%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DPreclinical%252Band%252BClinical%252BAdvances%252Bof%252BTargeted%252BProtein%252BDegradation%252Bas%252Ba%252BNovel%252BCancer%252BTherapeutic%252BStrategy%25253A%252BAn%252BOncologist%252BPerspective%26aulast%3DYang%26aufirst%3DXinrui%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D1%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gonzalo  Recondo</span>, <span class="hlFld-ContribAuthor ">Luc  Friboulet</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic strategies to overcome ALK resistance in lung cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 123-139. <a href="https://doi.org/10.1016/B978-0-12-821774-0.00004-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-821774-0.00004-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821774-0.00004-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821774-0.00004-8%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutic%252Bstrategies%252Bto%252Bovercome%252BALK%252Bresistance%252Bin%252Blung%252Bcancer%26aulast%3DRecondo%26aufirst%3DGonzalo%26date%3D2021%26spage%3D123%26epage%3D139%26pub%3DElsevier%26atitle%3DTherapeutic%252BStrategies%252Bto%252BOvercome%252BALK%252BResistance%252Bin%252BCancer%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shenxin  Zeng</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Zheng</span>, <span class="hlFld-ContribAuthor ">Liyan cheng</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112981. <a href="https://doi.org/10.1016/j.ejmech.2020.112981" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112981%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%252Bin%252Bdrug%252Bdiscovery%252Bparadigm%25253A%252BRecent%252Bprogress%252Band%252Bfuture%252Bchallenges%26aulast%3DZeng%26aufirst%3DShenxin%26date%3D2021%26volume%3D210%26spage%3D112981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Mologni</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>, <span class="hlFld-ContribAuthor ">Sara  Redaelli</span>, <span class="hlFld-ContribAuthor ">Alfonso  Zambon</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Kinase Targeting in Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/cancers13010119" title="DOI URL">https://doi.org/10.3390/cancers13010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13010119%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BKinase%252BTargeting%252Bin%252BLeukemia%26aulast%3DMologni%26aufirst%3DLuca%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Maneiro</span>, <span class="hlFld-ContribAuthor ">E.  De Vita</span>, <span class="hlFld-ContribAuthor ">D.  Conole</span>, <span class="hlFld-ContribAuthor ">C.S.  Kounde</span>, <span class="hlFld-ContribAuthor ">Q.  Zhang</span>, <span class="hlFld-ContribAuthor ">E.W.  Tate</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/bs.pmch.2021.01.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2021.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2021.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2021.01.002%26sid%3Dliteratum%253Aachs%26atitle%3DPROTACs%25252C%252Bmolecular%252Bglues%252Band%252Bbifunctionals%252Bfrom%252Bbench%252Bto%252Bbedside%25253A%252BUnlocking%252Bthe%252Bclinical%252Bpotential%252Bof%252Bcatalytic%252Bdrugs%26aulast%3DManeiro%26aufirst%3DM.%26date%3D2021%26pub%3DElsevier%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chelsea E.  Powell</span>, <span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jonathan W.  Bushman</span>, <span class="hlFld-ContribAuthor ">Zhixiang  He</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Selective degradation-inducing probes for studying cereblon (CRBN) biology. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>411 </em><a href="https://doi.org/10.1039/D0MD00382D" title="DOI URL">https://doi.org/10.1039/D0MD00382D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00382D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00382D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSelective%252Bdegradation-inducing%252Bprobes%252Bfor%252Bstudying%252Bcereblon%252B%252528CRBN%252529%252Bbiology%26aulast%3DPowell%26aufirst%3DChelsea%2BE.%26date%3D2021%26date%3D2021%26volume%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqing  Liang</span>, <span class="hlFld-ContribAuthor ">Kutty Selva  Nandakumar</span>, <span class="hlFld-ContribAuthor ">Kui  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design and pharmaceutical applications of proteolysis-targeting chimeric molecules. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114211. <a href="https://doi.org/10.1016/j.bcp.2020.114211" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114211</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114211%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDesign%252Band%252Bpharmaceutical%252Bapplications%252Bof%252Bproteolysis-targeting%252Bchimeric%252Bmolecules%26aulast%3DLiang%26aufirst%3DYuqing%26date%3D2020%26volume%3D182%26spage%3D114211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xi</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent small molecule PROTACs targeting mutant EGFR. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112781. <a href="https://doi.org/10.1016/j.ejmech.2020.112781" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112781%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bsmall%252Bmolecule%252BPROTACs%252Btargeting%252Bmutant%252BEGFR%26aulast%3DZhao%26aufirst%3DHong-Yi%26date%3D2020%26volume%3D208%26spage%3D112781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangyuan  Cao</span>, <span class="hlFld-ContribAuthor ">Sander  de Weerd</span>, <span class="hlFld-ContribAuthor ">Deng  Chen</span>, <span class="hlFld-ContribAuthor ">Martijn R.H.  Zwinderman</span>, <span class="hlFld-ContribAuthor ">Petra E.  van der Wouden</span>, <span class="hlFld-ContribAuthor ">Frank J.  Dekker</span>. </span><span class="cited-content_cbyCitation_article-title">Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112800. <a href="https://doi.org/10.1016/j.ejmech.2020.112800" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112800%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInduced%252Bprotein%252Bdegradation%252Bof%252Bhistone%252Bdeacetylases%252B3%252B%252528HDAC3%252529%252Bby%252Bproteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%26aulast%3DCao%26aufirst%3DFangyuan%26date%3D2020%26volume%3D208%26spage%3D112800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Iżykowska</span>, <span class="hlFld-ContribAuthor ">Karolina  Rassek</span>, <span class="hlFld-ContribAuthor ">Dorota  Korsak</span>, <span class="hlFld-ContribAuthor ">Grzegorz K.  Przybylski</span>. </span><span class="cited-content_cbyCitation_article-title">Novel targeted therapies of T cell lymphomas. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-01006-w" title="DOI URL">https://doi.org/10.1186/s13045-020-01006-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-01006-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-01006-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DNovel%252Btargeted%252Btherapies%252Bof%252BT%252Bcell%252Blymphomas%26aulast%3DI%25C5%25BCykowska%26aufirst%3DKatarzyna%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yonghan  He</span>, <span class="hlFld-ContribAuthor ">Sajid  Khan</span>, <span class="hlFld-ContribAuthor ">Zhiguang  Huo</span>, <span class="hlFld-ContribAuthor ">Dongwen  Lv</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xingui  Liu</span>, <span class="hlFld-ContribAuthor ">Yaxia  Yuan</span>, <span class="hlFld-ContribAuthor ">Robert  Hromas</span>, <span class="hlFld-ContribAuthor ">Mingjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Guangrong  Zheng</span>, <span class="hlFld-ContribAuthor ">Daohong  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00924-z" title="DOI URL">https://doi.org/10.1186/s13045-020-00924-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00924-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00924-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DProteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bare%252Bemerging%252Btherapeutics%252Bfor%252Bhematologic%252Bmalignancies%26aulast%3DHe%26aufirst%3DYonghan%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Feral</span>, <span class="hlFld-ContribAuthor ">Guillaume  Laconde</span>, <span class="hlFld-ContribAuthor ">Muriel  Amblard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Masurier</span>. </span><span class="cited-content_cbyCitation_article-title">PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (11)
                                     , 2000148. <a href="https://doi.org/10.1002/adtp.202000148" title="DOI URL">https://doi.org/10.1002/adtp.202000148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000148%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DPROteolysis%252BTArgetting%252BChimeras%252B%252528PROTACs%252529%252BStrategy%252BApplied%252Bto%252BKinases%25253A%252BRecent%252BAdvances%26aulast%3DFeral%26aufirst%3DAnthony%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D11%26spage%3D2000148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lina  Yin</span>, <span class="hlFld-ContribAuthor ">Qingzhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Chimera induced protein degradation: PROTACs and beyond. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112494. <a href="https://doi.org/10.1016/j.ejmech.2020.112494" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112494</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112494%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChimera%252Binduced%252Bprotein%252Bdegradation%25253A%252BPROTACs%252Band%252Bbeyond%26aulast%3DYin%26aufirst%3DLina%26date%3D2020%26volume%3D206%26spage%3D112494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuhua  Zheng</span>, <span class="hlFld-ContribAuthor ">Wensi  Tao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.01517" title="DOI URL">https://doi.org/10.3389/fonc.2020.01517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.01517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.01517%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DTargeting%252BCullin-RING%252BE3%252BLigases%252Bfor%252BRadiosensitization%25253A%252BFrom%252BNEDDylation%252BInhibition%252Bto%252BPROTACs%26aulast%3DZheng%26aufirst%3DShuhua%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Ciric  To</span>, <span class="hlFld-ContribAuthor ">Dries J. H.  De Clercq</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Park</span>, <span class="hlFld-ContribAuthor ">Charles M.  Ponthier</span>, <span class="hlFld-ContribAuthor ">Bo Hee  Shin</span>, <span class="hlFld-ContribAuthor ">Mierzhati  Mushajiang</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (34)
                                     , 14589-14597. <a href="https://doi.org/10.1002/ange.202003500" title="DOI URL">https://doi.org/10.1002/ange.202003500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202003500%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DMutant%2525E2%252580%252590Selective%252BAllosteric%252BEGFR%252BDegraders%252Bare%252BEffective%252BAgainst%252Ba%252BBroad%252BRange%252Bof%252BDrug%2525E2%252580%252590Resistant%252BMutations%26aulast%3DJang%26aufirst%3DJaebong%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D34%26spage%3D14589%26epage%3D14597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Ciric  To</span>, <span class="hlFld-ContribAuthor ">Dries J. H.  De Clercq</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Park</span>, <span class="hlFld-ContribAuthor ">Charles M.  Ponthier</span>, <span class="hlFld-ContribAuthor ">Bo Hee  Shin</span>, <span class="hlFld-ContribAuthor ">Mierzhati  Mushajiang</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (34)
                                     , 14481-14489. <a href="https://doi.org/10.1002/anie.202003500" title="DOI URL">https://doi.org/10.1002/anie.202003500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202003500%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DMutant%2525E2%252580%252590Selective%252BAllosteric%252BEGFR%252BDegraders%252Bare%252BEffective%252BAgainst%252Ba%252BBroad%252BRange%252Bof%252BDrug%2525E2%252580%252590Resistant%252BMutations%26aulast%3DJang%26aufirst%3DJaebong%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D34%26spage%3D14481%26epage%3D14489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dhanusha A.  Nalawansha</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs: An Emerging Therapeutic Modality in Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (8)
                                     , 998-1014. <a href="https://doi.org/10.1016/j.chembiol.2020.07.020" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.07.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.07.020%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DPROTACs%25253A%252BAn%252BEmerging%252BTherapeutic%252BModality%252Bin%252BPrecision%252BMedicine%26aulast%3DNalawansha%26aufirst%3DDhanusha%2BA.%26date%3D2020%26volume%3D27%26issue%3D8%26spage%3D998%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sajid  Khan</span>, <span class="hlFld-ContribAuthor ">Yonghan  He</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yaxia  Yuan</span>, <span class="hlFld-ContribAuthor ">Shaoyan  Pu</span>, <span class="hlFld-ContribAuthor ">Qingpeng  Kong</span>, <span class="hlFld-ContribAuthor ">Guangrong  Zheng</span>, <span class="hlFld-ContribAuthor ">Daohong  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2020,</strong> <em>39 </em>
                                    (26)
                                     , 4909-4924. <a href="https://doi.org/10.1038/s41388-020-1336-y" title="DOI URL">https://doi.org/10.1038/s41388-020-1336-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-020-1336-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-020-1336-y%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DPROteolysis%252BTArgeting%252BChimeras%252B%252528PROTACs%252529%252Bas%252Bemerging%252Banticancer%252Btherapeutics%26aulast%3DKhan%26aufirst%3DSajid%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D26%26spage%3D4909%26epage%3D4924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carina  Cantrill</span>, <span class="hlFld-ContribAuthor ">Prasoon  Chaturvedi</span>, <span class="hlFld-ContribAuthor ">Caroline  Rynn</span>, <span class="hlFld-ContribAuthor ">Jeannine  Petrig Schaffland</span>, <span class="hlFld-ContribAuthor ">Isabelle  Walter</span>, <span class="hlFld-ContribAuthor ">Matthias B.  Wittwer</span>. </span><span class="cited-content_cbyCitation_article-title">Fundamental aspects of DMPK optimization of targeted protein degraders. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (6)
                                     , 969-982. <a href="https://doi.org/10.1016/j.drudis.2020.03.012" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DFundamental%252Baspects%252Bof%252BDMPK%252Boptimization%252Bof%252Btargeted%252Bprotein%252Bdegraders%26aulast%3DCantrill%26aufirst%3DCarina%26date%3D2020%26volume%3D25%26issue%3D6%26spage%3D969%26epage%3D982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning  Sun</span>, <span class="hlFld-ContribAuthor ">Chaowei  Ren</span>, <span class="hlFld-ContribAuthor ">Ying  Kong</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinju  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Jianshui  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuedong  Zhou</span>, <span class="hlFld-ContribAuthor ">Xing  Qiu</span>, <span class="hlFld-ContribAuthor ">Haifan  Lin</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Song</span>, <span class="hlFld-ContribAuthor ">Xiaobao  Yang</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>193 </em>, 112190. <a href="https://doi.org/10.1016/j.ejmech.2020.112190" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112190%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BBrigatinib%252Bdegrader%252B%252528SIAIS117%252529%252Bas%252Ba%252Bpotential%252Btreatment%252Bfor%252BALK%252Bpositive%252Bcancer%252Bresistance%26aulast%3DSun%26aufirst%3DNing%26date%3D2020%26volume%3D193%26spage%3D112190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Milka  Kostic</span>, <span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2020,</strong> <em>41 </em>
                                    (5)
                                     , 305-317. <a href="https://doi.org/10.1016/j.tips.2020.02.006" title="DOI URL">https://doi.org/10.1016/j.tips.2020.02.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.02.006%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DCritical%252BAssessment%252Bof%252BTargeted%252BProtein%252BDegradation%252Bas%252Ba%252BResearch%252BTool%252Band%252BPharmacological%252BModality%26aulast%3DKostic%26aufirst%3DMilka%26date%3D2020%26volume%3D41%26issue%3D5%26spage%3D305%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Gasic</span>, <span class="hlFld-ContribAuthor ">Brian J.  Groendyke</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">J. Christine  Yuan</span>, <span class="hlFld-ContribAuthor ">Joann  Kalabathula</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Mitchison</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin Resists Degradation by Cereblon-Recruiting PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (5)
                                     , 1083. <a href="https://doi.org/10.3390/cells9051083" title="DOI URL">https://doi.org/10.3390/cells9051083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9051083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9051083%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTubulin%252BResists%252BDegradation%252Bby%252BCereblon-Recruiting%252BPROTACs%26aulast%3DGasic%26aufirst%3DIvana%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D5%26spage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yichao  Wan</span>, <span class="hlFld-ContribAuthor ">Chunxing  Yan</span>, <span class="hlFld-ContribAuthor ">Han  Gao</span>, <span class="hlFld-ContribAuthor ">Tingting  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule PROTACs: novel agents for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 915-938. <a href="https://doi.org/10.4155/fmc-2019-0340" title="DOI URL">https://doi.org/10.4155/fmc-2019-0340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0340%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DSmall-molecule%252BPROTACs%25253A%252Bnovel%252Bagents%252Bfor%252Bcancer%252Btherapy%26aulast%3DWan%26aufirst%3DYichao%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D915%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingming  Wang</span>, <span class="hlFld-ContribAuthor ">Lingfei  Han</span>, <span class="hlFld-ContribAuthor ">Fulei  Liu</span>, <span class="hlFld-ContribAuthor ">Fubai  Yang</span>, <span class="hlFld-ContribAuthor ">Xueyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Jingwei  Xue</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces B: Biointerfaces</span><span> <strong>2020,</strong> <em>188 </em>, 110795. <a href="https://doi.org/10.1016/j.colsurfb.2020.110795" title="DOI URL">https://doi.org/10.1016/j.colsurfb.2020.110795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfb.2020.110795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfb.2020.110795%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520B%253A%2520Biointerfaces%26atitle%3DTargeted%252Bdegradation%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bby%252Bgold%252Bnanoparticle-based%252Bmulti-headed%252Bproteolysis%252Btargeting%252Bchimeras%26aulast%3DWang%26aufirst%3DYingming%26date%3D2020%26volume%3D188%26spage%3D110795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhou</span>, <span class="hlFld-ContribAuthor ">Luyu  Chen</span>, <span class="hlFld-ContribAuthor ">Chaoguo  Cao</span>, <span class="hlFld-ContribAuthor ">Jiang  Yu</span>, <span class="hlFld-ContribAuthor ">Xiaojiao  Luo</span>, <span class="hlFld-ContribAuthor ">Peiting  Zhou</span>, <span class="hlFld-ContribAuthor ">Lifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Wu  Du</span>, <span class="hlFld-ContribAuthor ">Jijun  Cheng</span>, <span class="hlFld-ContribAuthor ">Yongmei  Xie</span>, <span class="hlFld-ContribAuthor ">Yuanwei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of selective mono or dual PROTAC degrader probe of CDK isoforms. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111952. <a href="https://doi.org/10.1016/j.ejmech.2019.111952" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111952%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bselective%252Bmono%252Bor%252Bdual%252BPROTAC%252Bdegrader%252Bprobe%252Bof%252BCDK%252Bisoforms%26aulast%3DZhou%26aufirst%3DFei%26date%3D2020%26volume%3D187%26spage%3D111952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rati  Verma</span>, <span class="hlFld-ContribAuthor ">Dane  Mohl</span>, <span class="hlFld-ContribAuthor ">Raymond J.  Deshaies</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing the Power of Proteolysis for Targeted Protein Inactivation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2020,</strong> <em>77 </em>
                                    (3)
                                     , 446-460. <a href="https://doi.org/10.1016/j.molcel.2020.01.010" title="DOI URL">https://doi.org/10.1016/j.molcel.2020.01.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2020.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2020.01.010%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DHarnessing%252Bthe%252BPower%252Bof%252BProteolysis%252Bfor%252BTargeted%252BProtein%252BInactivation%26aulast%3DVerma%26aufirst%3DRati%26date%3D2020%26volume%3D77%26issue%3D3%26spage%3D446%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Reynders</span>, <span class="hlFld-ContribAuthor ">Bryan S.  Matsuura</span>, <span class="hlFld-ContribAuthor ">Marleen  Bérouti</span>, <span class="hlFld-ContribAuthor ">Daniele  Simoneschi</span>, <span class="hlFld-ContribAuthor ">Antonio  Marzio</span>, <span class="hlFld-ContribAuthor ">Michele  Pagano</span>, <span class="hlFld-ContribAuthor ">Dirk  Trauner</span>. </span><span class="cited-content_cbyCitation_article-title">PHOTACs enable optical control of protein degradation. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2020,</strong> <em>6 </em>
                                    (8)
                                     , eaay5064. <a href="https://doi.org/10.1126/sciadv.aay5064" title="DOI URL">https://doi.org/10.1126/sciadv.aay5064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.aay5064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.aay5064%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DPHOTACs%252Benable%252Boptical%252Bcontrol%252Bof%252Bprotein%252Bdegradation%26aulast%3DReynders%26aufirst%3DMartin%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D8%26spage%3Deaay5064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei  Zeng</span>, <span class="hlFld-ContribAuthor ">Yuan  Xiong</span>, <span class="hlFld-ContribAuthor ">Nozhat  Safaee</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Christine J.  Yuan</span>, <span class="hlFld-ContribAuthor ">Behnam  Nabet</span>, <span class="hlFld-ContribAuthor ">Thomas W.  Gero</span>, <span class="hlFld-ContribAuthor ">Frederic  Feru</span>, <span class="hlFld-ContribAuthor ">Lianbo  Li</span>, <span class="hlFld-ContribAuthor ">Sudershan  Gondi</span>, <span class="hlFld-ContribAuthor ">Lincoln J.  Ombelets</span>, <span class="hlFld-ContribAuthor ">Chunshan  Quan</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Milka  Kostic</span>, <span class="hlFld-ContribAuthor ">David A.  Scott</span>, <span class="hlFld-ContribAuthor ">Kenneth D.  Westover</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (1)
                                     , 19-31.e6. <a href="https://doi.org/10.1016/j.chembiol.2019.12.006" title="DOI URL">https://doi.org/10.1016/j.chembiol.2019.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2019.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2019.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DExploring%252BTargeted%252BDegradation%252BStrategy%252Bfor%252BOncogenic%252BKRASG12C%26aulast%3DZeng%26aufirst%3DMei%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D19%26epage%3D31.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuyun  Sun</span>, <span class="hlFld-ContribAuthor ">Hongying  Gao</span>, <span class="hlFld-ContribAuthor ">Yiqing  Yang</span>, <span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Yugang  Song</span>, <span class="hlFld-ContribAuthor ">Yan  Tong</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs: great opportunities for academia and industry. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-019-0101-6" title="DOI URL">https://doi.org/10.1038/s41392-019-0101-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DPROTACs%25253A%252Bgreat%252Bopportunities%252Bfor%252Bacademia%252Band%252Bindustry%26aulast%3DSun%26aufirst%3DXiuyun%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthieu  Schapira</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Calabrese</span>, <span class="hlFld-ContribAuthor ">Alex N.  Bullock</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted protein degradation: expanding the toolbox. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2019,</strong> <em>18 </em>
                                    (12)
                                     , 949-963. <a href="https://doi.org/10.1038/s41573-019-0047-y" title="DOI URL">https://doi.org/10.1038/s41573-019-0047-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DTargeted%252Bprotein%252Bdegradation%25253A%252Bexpanding%252Bthe%252Btoolbox%26aulast%3DSchapira%26aufirst%3DMatthieu%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D12%26spage%3D949%26epage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah J.  Maple</span>, <span class="hlFld-ContribAuthor ">Nat  Clayden</span>, <span class="hlFld-ContribAuthor ">Anne  Baron</span>, <span class="hlFld-ContribAuthor ">Callum  Stacey</span>, <span class="hlFld-ContribAuthor ">Robert  Felix</span>. </span><span class="cited-content_cbyCitation_article-title">Developing degraders: principles and perspectives on design and chemical space. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1755-1764. <a href="https://doi.org/10.1039/C9MD00272C" title="DOI URL">https://doi.org/10.1039/C9MD00272C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00272C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00272C%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDeveloping%252Bdegraders%25253A%252Bprinciples%252Band%252Bperspectives%252Bon%252Bdesign%252Band%252Bchemical%252Bspace%26aulast%3DMaple%26aufirst%3DHannah%2BJ.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1755%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomoko  Asatsuma-Okumura</span>, <span class="hlFld-ContribAuthor ">Takumi  Ito</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Handa</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of cereblon-based drugs. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>202 </em>, 132-139. <a href="https://doi.org/10.1016/j.pharmthera.2019.06.004" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DMolecular%252Bmechanisms%252Bof%252Bcereblon-based%252Bdrugs%26aulast%3DAsatsuma-Okumura%26aufirst%3DTomoko%26date%3D2019%26volume%3D202%26spage%3D132%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sascha  Röth</span>, <span class="hlFld-ContribAuthor ">Luke J.  Fulcher</span>, <span class="hlFld-ContribAuthor ">Gopal P.  Sapkota</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in targeted degradation of endogenous proteins. </span><span class="cited-content_cbyCitation_journal-name">Cellular and Molecular Life Sciences</span><span> <strong>2019,</strong> <em>76 </em>
                                    (14)
                                     , 2761-2777. <a href="https://doi.org/10.1007/s00018-019-03112-6" title="DOI URL">https://doi.org/10.1007/s00018-019-03112-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00018-019-03112-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00018-019-03112-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520and%2520Molecular%2520Life%2520Sciences%26atitle%3DAdvances%252Bin%252Btargeted%252Bdegradation%252Bof%252Bendogenous%252Bproteins%26aulast%3DR%25C3%25B6th%26aufirst%3DSascha%26date%3D2019%26date%3D2019%26volume%3D76%26issue%3D14%26spage%3D2761%26epage%3D2777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott D.  Edmondson</span>, <span class="hlFld-ContribAuthor ">Bin  Yang</span>, <span class="hlFld-ContribAuthor ">Charlene  Fallan</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (13)
                                     , 1555-1564. <a href="https://doi.org/10.1016/j.bmcl.2019.04.030" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DProteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bin%252B%2525E2%252580%252598beyond%252Brule-of-five%2525E2%252580%252599%252Bchemical%252Bspace%25253A%252BRecent%252Bprogress%252Band%252Bfuture%252Bchallenges%26aulast%3DEdmondson%26aufirst%3DScott%2BD.%26date%3D2019%26volume%3D29%26issue%3D13%26spage%3D1555%26epage%3D1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stacey-Lynn  Paiva</span>, <span class="hlFld-ContribAuthor ">Craig M  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted protein degradation: elements of PROTAC design. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 111-119. <a href="https://doi.org/10.1016/j.cbpa.2019.02.022" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.02.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.02.022%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTargeted%252Bprotein%252Bdegradation%25253A%252Belements%252Bof%252BPROTAC%252Bdesign%26aulast%3DPaiva%26aufirst%3DStacey-Lynn%26date%3D2019%26volume%3D50%26spage%3D111%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danette L.  Daniels</span>, <span class="hlFld-ContribAuthor ">Kristin M.  Riching</span>, <span class="hlFld-ContribAuthor ">Marjeta  Urh</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring and deciphering protein degradation pathways inside cells. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2019,</strong> <em>31 </em>, 61-68. <a href="https://doi.org/10.1016/j.ddtec.2018.12.001" title="DOI URL">https://doi.org/10.1016/j.ddtec.2018.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2018.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2018.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DMonitoring%252Band%252Bdeciphering%252Bprotein%252Bdegradation%252Bpathways%252Binside%252Bcells%26aulast%3DDaniels%26aufirst%3DDanette%2BL.%26date%3D2019%26volume%3D31%26spage%3D61%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Norihito  Shibata</span>, <span class="hlFld-ContribAuthor ">Nobumichi  Ohoka</span>, <span class="hlFld-ContribAuthor ">Takayuki  Hattori</span>, <span class="hlFld-ContribAuthor ">Mikihiko  Naito</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2019,</strong> <em>67 </em>
                                    (3)
                                     , 165-172. <a href="https://doi.org/10.1248/cpb.c18-00703" title="DOI URL">https://doi.org/10.1248/cpb.c18-00703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c18-00703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c18-00703%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDevelopment%252Bof%252Ba%252BPotent%252BProtein%252BDegrader%252Bagainst%252BOncogenic%252BBCR-ABL%252BProtein%26aulast%3DShibata%26aufirst%3DNorihito%26date%3D2019%26volume%3D67%26issue%3D3%26spage%3D165%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuye  Zhao</span>, <span class="hlFld-ContribAuthor ">Tianlong  Lan</span>, <span class="hlFld-ContribAuthor ">Shang  Su</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (3)
                                     , 369-372. <a href="https://doi.org/10.1039/C8CC07813K" title="DOI URL">https://doi.org/10.1039/C8CC07813K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC07813K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC07813K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DInduction%252Bof%252Bapoptosis%252Bin%252BMDA-MB-231%252Bbreast%252Bcancer%252Bcells%252Bby%252Ba%252BPARP1-targeting%252BPROTAC%252Bsmall%252Bmolecule%26aulast%3DZhao%26aufirst%3DQiuye%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D3%26spage%3D369%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yutian  Zou</span>, <span class="hlFld-ContribAuthor ">Danhui  Ma</span>, <span class="hlFld-ContribAuthor ">Yinyin  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The PROTAC technology in drug development. </span><span class="cited-content_cbyCitation_journal-name">Cell Biochemistry and Function</span><span> <strong>2019,</strong> <em>37 </em>
                                    (1)
                                     , 21-30. <a href="https://doi.org/10.1002/cbf.3369" title="DOI URL">https://doi.org/10.1002/cbf.3369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbf.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbf.3369%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Biochemistry%2520and%2520Function%26atitle%3DThe%252BPROTAC%252Btechnology%252Bin%252Bdrug%252Bdevelopment%26aulast%3DZou%26aufirst%3DYutian%26date%3D2019%26date%3D2019%26volume%3D37%26issue%3D1%26spage%3D21%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chung Hyo  Kang</span>, <span class="hlFld-ContribAuthor ">Dong Ho  Lee</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Jae  Du Ha</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>. </span><span class="cited-content_cbyCitation_article-title">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2018,</strong> <em>505 </em>
                                    (2)
                                     , 542-547. <a href="https://doi.org/10.1016/j.bbrc.2018.09.169" title="DOI URL">https://doi.org/10.1016/j.bbrc.2018.09.169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DInduced%252Bprotein%252Bdegradation%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Bby%252Bproteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%26aulast%3DKang%26aufirst%3DChung%2BHyo%26date%3D2018%26volume%3D505%26issue%3D2%26spage%3D542%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Li</span>, <span class="hlFld-ContribAuthor ">Rammohan R. Yadav  Bheemanaboina</span>, <span class="hlFld-ContribAuthor ">Narsaiah  Battini</span>, <span class="hlFld-ContribAuthor ">Vijai Kumar Reddy  Tangadanchu</span>, <span class="hlFld-ContribAuthor ">Xian-Fu  Fang</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant
              Staphylococcus aureus. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 1529-1537. <a href="https://doi.org/10.1039/C8MD00301G" title="DOI URL">https://doi.org/10.1039/C8MD00301G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00301G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00301G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DNovel%252Borganophosphorus%252Baminopyrimidines%252Bas%252Bunique%252Bstructural%252BDNA-targeting%252Bmembrane%252Bactive%252Binhibitors%252Btowards%252Bdrug-resistant%252Bmethicillin-resistant%252BStaphylococcus%252Baureus%26aulast%3DLi%26aufirst%3DDi%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D9%26spage%3D1529%26epage%3D1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures and characterization of ALK degraders. (A) TAE684 is the parental kinase inhibitor of <b>9</b> and <b>10</b>. LDK378 is the parental inhibitor of <b>11</b> and <b>12</b>. <b>9</b> and <b>11</b> are ALK targeted degraders, while <b>10</b> and <b>12</b> contain des-carbonyl versions of the pomalidomide group, causing them to exhibit substantially weakened binding to cereblon. (B) TR-FRET ALK activity assay, plotted as the mean of three technical replicates ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Antiproliferative best fit EC<sub>50</sub> values with 95% CI in NSCLC and ALCL cell lines after 72 h treatments (three biological replicates; Graphpad Prism 7 software).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Degrader behavior in H3122 and Karpas 299 cells. (A) Immunoblots after 16 h of treatment with dose titrations of <b>9</b> and <b>11</b>. (B) Immunoblots after treatment with 250 nM compound for the indicated amount of time. (C) Immunoblots after 2 h pretreatments with DMSO, carfilzomib (Car), MLN4924 (MLN), pomalidomide (Pom), TAE684, or LDK378 followed by 16 h treatments with <b>9</b> or <b>11</b>. (D) Immunoblots of downstream ALK signaling after 16 h compound treatments; t-ALK indicates total ALK, and p-ALK indicates phosphorylated ALK. (E) Immunoblots of sustained downstream ALK signaling after the indicated treatment times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Antiproliferative best fit EC<sub>50</sub> values with 95% CI in NB cell lines after 72 h treatments (two biological replicates; GraphPad Prism 7 software: ∗ = upper CI not calculated by model). 125 nM tariquidar (Tari.) was used for the indicated cotreatments. (B) Immunoblot of ABCB1 expression in NB lysates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Degrader behavior in Kelly and CHLA20 cells. (A) Immunoblots after 16 h of treatment with dose titrations of <b>9</b> and <b>11</b>. Tari. indicates tariquidar. (B) Immunoblots after treatment with 100 nM compound for the indicated amount of time. (C) Immunoblots after 2 h pretreatments with DMSO, carfilzomib (Car), MLN4924 (MLN), pomalidomide (Pom), TAE684, or LDK378 followed by 16 h treatments with <b>9</b> and <b>11</b>. (D) Immunoblots of downstream ALK signaling after 16 h compound treatments; t-ALK indicates total ALK, and p-ALK indicates phosphorylated ALK. (E) Immunoblots of sustained downstream ALK signaling after the indicated treatment times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/medium/jm-2017-01655v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>9</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01655&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i18">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The Anaplastic Lymphoma Kinase in the Pathogenesis of Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+Anaplastic+Lymphoma+Kinase+in+the+Pathogenesis+of+Cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0ljoylJ5jfjXxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520the%2520Pathogenesis%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK): Structure, Oncogenic Activation, and Pharmacological Inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29%3A+Structure%2C+Oncogenic+Activation%2C+and+Pharmacological+Inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0liN5298lbXuJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%253A%2520Structure%252C%2520Oncogenic%2520Activation%252C%2520and%2520Pharmacological%2520Inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms that Underpin EML4-ALK Driven Cancers and Their Response to Targeted Drugs</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-2117-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1007%2Fs00018-015-2117-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26755435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1209-1224&author=R.+Baylissauthor=J.+Choiauthor=D.+A.+Fennellauthor=A.+M.+Fryauthor=M.+W.+Richards&title=Molecular+Mechanisms+that+Underpin+EML4-ALK+Driven+Cancers+and+Their+Response+to+Targeted+Drugs&doi=10.1007%2Fs00018-015-2117-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs</span></div><div class="casAuthors">Bayliss, Richard; Choi, Jene; Fennell, Dean A.; Fry, Andrew M.; Richards, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1209-1224</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A fusion between the EML4 (echinoderm microtubule-assocd. protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit of patients.  However, we have a poor understanding of EML4 and ALK biol. and there are many challenges to devising the optimal strategy for treating EML4-ALK NSCLC patients.  In this review, we describe the biol. of EML4 and ALK, explain the main features of EML4-ALK fusion proteins and outline the therapies that target EML4-ALK.  In particular, we highlight the recent advances in our understanding of the structures of EML proteins, describe the mol. mechanisms of resistance to ALK inhibitors and assess current thinking about combinations of ALK drugs with inhibitors that target other kinases or Hsp90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUKOVGNalV9LVg90H21EOLACvtfcHk0liN5298lbXuJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOiuw%253D%253D&md5=9fbba0e0d4c49c4ffdc0dfaef6f19798</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2117-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2117-6%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DD.%2BA.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26atitle%3DMolecular%2520Mechanisms%2520that%2520Underpin%2520EML4-ALK%2520Driven%2520Cancers%2520and%2520Their%2520Response%2520to%2520Targeted%2520Drugs%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D1209%26epage%3D1224%26doi%3D10.1007%2Fs00018-015-2117-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Activating Mutations in ALK Provide a Therapeutic Target in Neuroblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+Mutations+in+ALK+Provide+a+Therapeutic+Target+in+Neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520Mutations%2520in%2520ALK%2520Provide%2520a%2520Therapeutic%2520Target%2520in%2520Neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0linxG0EBRb95A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernersson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase: Signalling in Development and Disease</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+Lymphoma+Kinase%3A+Signalling+in+Development+and+Disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%253A%2520Signalling%2520in%2520Development%2520and%2520Disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the Chromosome 2 Gene Locus Altered by the t(2;5) in Non-Hodgkin’s Lymphoma, Encodes a Novel Neural Receptor Tyrosine Kinase that is Highly Related to Leukocyte Tyrosine Kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+Chromosome+2+Gene+Locus+Altered+by+the+t%282%3B5%29+in+Non-Hodgkin%E2%80%99s+Lymphoma%2C+Encodes+a+Novel+Neural+Receptor+Tyrosine+Kinase+that+is+Highly+Related+to+Leukocyte+Tyrosine+Kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0lhgxxYnjH792w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520Chromosome%25202%2520Gene%2520Locus%2520Altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%252C%2520Encodes%2520a%2520Novel%2520Neural%2520Receptor%2520Tyrosine%2520Kinase%2520that%2520is%2520Highly%2520Related%2520to%2520Leukocyte%2520Tyrosine%2520Kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib Versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1704795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1056%2FNEJMoa1704795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=28586279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=829-838&author=S.+Petersauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=S.+Gadgeelauthor=J.+S.+Ahnauthor=D.-W.+Kimauthor=S.-H.+I.+Ouauthor=M.+P%C3%A9rolauthor=R.+Dziadziuszkoauthor=R.+Rosellauthor=A.+Zeaiterauthor=E.+Mitryauthor=S.+Goldingauthor=B.+Balasauthor=J.+Noeauthor=P.+N.+Morcosauthor=T.+Mok&title=Alectinib+Versus+Crizotinib+in+Untreated+ALK-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1704795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span></div><div class="casAuthors">Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-pos. non-small-cell lung cancer (NSCLC).  We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-pos. NSCLC, including those with asymptomatic CNS disease.  METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-pos. NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily).  The primary end point was investigator assessed progression-free survival.  Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.  RESULTS: During a median follow-up of 17.6 mo (crizotinib) and 18.6 mo (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group.  The rate of investigator- assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-mo event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached.  The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point.  A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001).  A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P = 0.09).  Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).  CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaWsEV8z16LVg90H21EOLACvtfcHk0lhZIp4nEpks_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL&md5=cb58ab7eb5b266a3d292eb714a1c8104</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1704795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1704795%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DMitry%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DAlectinib%2520Versus%2520Crizotinib%2520in%2520Untreated%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D829%26epage%3D838%26doi%3D10.1056%2FNEJMoa1704795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr</span></span> <span> </span><span class="NLM_article-title">First-Line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-Rearranged Non-Small-Cell Lung Cancer (ASCEND-4): a Randomised, Open-Label, Phase 3 Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.-C.+Soriaauthor=D.+S.+W.+Tanauthor=R.+Chiariauthor=Y.-L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L.+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.-J.+Yuauthor=M.+Hochmairauthor=A.+B.+Cortotauthor=C.-M.+Tsaiauthor=D.+Moro-Sibilotauthor=R.+G.+Campeloauthor=T.+McCullochauthor=P.+Senauthor=M.+Duganauthor=S.+Pantanoauthor=F.+Branleauthor=C.+Massacesiauthor=G.+de+Castro&title=First-Line+Ceritinib+Versus+Platinum-Based+Chemotherapy+in+Advanced+ALK-Rearranged+Non-Small-Cell+Lung+Cancer+%28ASCEND-4%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0lhZIp4nEpks_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DHochmair%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCampelo%26aufirst%3DR.%2BG.%26aulast%3DMcCulloch%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DBranle%26aufirst%3DF.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26atitle%3DFirst-Line%2520Ceritinib%2520Versus%2520Platinum-Based%2520Chemotherapy%2520in%2520Advanced%2520ALK-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ASCEND-4%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessop, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">120ra17</span>– <span class="NLM_lpage">120ra17</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17-120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+Acquired+Crizotinib+Resistance+in+ALK-Rearranged+Lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520Acquired%2520Crizotinib%2520Resistance%2520in%2520ALK-Rearranged%2520Lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26epage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, C.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1177/1060028014553619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1177%2F1060028014553619" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=107-112&author=M.+R.+Cooperauthor=H.+Chimauthor=H.+Chanauthor=C.+Durand&title=Ceritinib%3A+A+New+Tyrosine+Kinase+Inhibitor+for+Non-Small-Cell+Lung+Cancer&doi=10.1177%2F1060028014553619"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1060028014553619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028014553619%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DChim%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDurand%26aufirst%3DC.%26atitle%3DCeritinib%253A%2520A%2520New%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2015%26volume%3D49%26spage%3D107%26epage%3D112%26doi%3D10.1177%2F1060028014553619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">ALK Inhibitors in Non-Small Cell Lung Cancer: the Latest Evidence and Developments</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1177/1758834015617355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1177%2F1758834015617355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26753004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=32-47&author=I.+Sullivanauthor=D.+Planchard&title=ALK+Inhibitors+in+Non-Small+Cell+Lung+Cancer%3A+the+Latest+Evidence+and+Developments&doi=10.1177%2F1758834015617355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: the latest evidence and developments</span></div><div class="casAuthors">Sullivan, Ivana; Planchard, David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small mol. inhibitor of ALK, ROS1 and MET.  Unfortunately, the disease progressed within the first 12 mo in most of the patients because of the development of crizotinib resistance in the majority of patients and the emergence of acquired resistance mutations in most of them.  Many of them had been reported even before its approval leading to the rapid development of second-generation ALK inhibitors for crizotinibresistant NSCLC.  In the last few years, novel potent ALK inhibitors with promising results and a good toxicity profile have become available: ceritinib (LDK378), alectinib (RG7853/ AF-802/RO5424802/CH5424802), brigatinib (AP26113), entrectinib (RXDX-101, NMS-E628), PF-06463922, ASP3026, TSR-011, X-376/X-396 and CEP-28122/CEP-37440.  Moreover, HSP90 (90 kDa heat shock protein) inhibitors have demonstrated clin. activity in patients with ALK+ NSCLC.  This review focuses on the mol. and clin. properties of this new generation of ALK inhibitors under development in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmT62DyyrILVg90H21EOLACvtfcHk0lgUI_Liz-Dh7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE&md5=9266542af3ea2ad9aadde47361105372</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1758834015617355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015617355%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520the%2520Latest%2520Evidence%2520and%2520Developments%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D8%26spage%3D32%26epage%3D47%26doi%3D10.1177%2F1758834015617355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span> <span> </span><span class="NLM_article-title">Expanding the Portfolio of Anti-ALK Weapons</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2014.07.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.3978%2Fj.issn.2218-6751.2014.07.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25806340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=5-7&author=L.+Mologni&title=Expanding+the+Portfolio+of+Anti-ALK+Weapons&doi=10.3978%2Fj.issn.2218-6751.2014.07.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the portfolio of anti-ALK weapons</span></div><div class="casAuthors">Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-7</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the onset of several malignancies.  In particular, ALK is the driving oncogenic lesion in a small but significant fraction of non-small cell lung cancer (NSCLC) patients.  ALK+ NSCLCs can be treated with the dual ALK/MET inhibitor crizotinib, with better outcome compared to std. chemotherapy.  However, relapses frequently occur, due to various mechanisms, limiting overall efficacy of the treatment.  Point mutations within the ALK catalytic domain or ALK gene amplification account for approx. 30-40% of crizotinib-resistant cases, suggesting that the diseases still relies on ALK activity and that more potent inhibitors could be useful in this setting.  Ceritinib is a novel selective ALK inhibitor with preclin. activity against crizotinib-resistant ALK mutants.  A recent article in the New England Journal of Medicine reports on clin. evaluation of ceritinib.  Response rate and progression-free survival (PFS) were comparable to crizotinib, but most importantly, crizotinib-resistant patients were successfully treated, with efficacy similar to crizotinib-na.ovrddot.ive patients.  The study extends the array of available anti-ALK drugs.  Based on these data, ceritinib was approved by FDA in Apr. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3jQk-1XeaLVg90H21EOLACvtfcHk0liGigdYS5DZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCmt7vJ&md5=f46c7192a6c48ba162d53beda5f6c23a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2014.07.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2014.07.02%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DExpanding%2520the%2520Portfolio%2520of%2520Anti-ALK%2520Weapons%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D5%26epage%3D7%26doi%3D10.3978%2Fj.issn.2218-6751.2014.07.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5686</span>– <span class="NLM_lpage">5696</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+Novel+ALK+Mutations+Mediate+Acquired+Resistance+to+the+Next-Generation+ALK+Inhibitor+Alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0liGigdYS5DZzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520Novel%2520ALK%2520Mutations%2520Mediate%2520Acquired%2520Resistance%2520to%2520the%2520Next-Generation%2520ALK%2520Inhibitor%2520Alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span> <span> </span><span class="NLM_article-title">The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions</span>. <i>Targeted Oncology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1007/s11523-017-0526-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1007%2Fs11523-017-0526-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=709-718&author=A.+Qinauthor=S.+Gadgeel&title=The+Current+Landscape+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+in+Non-Small+Cell+Lung+Cancer%3A+Emerging+Treatment+Paradigms+and+Future+Directions&doi=10.1007%2Fs11523-017-0526-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0526-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0526-1%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DA.%26aulast%3DGadgeel%26aufirst%3DS.%26atitle%3DThe%2520Current%2520Landscape%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Emerging%2520Treatment%2520Paradigms%2520and%2520Future%2520Directions%26jtitle%3DTargeted%2520Oncology%26date%3D2017%26volume%3D12%26spage%3D709%26epage%3D718%26doi%3D10.1007%2Fs11523-017-0526-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+Crizotinib+by+the+Lorlatinib+ALK+Resistance+Mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0lgcINc1mSG-ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520Crizotinib%2520by%2520the%2520Lorlatinib%2520ALK%2520Resistance%2520Mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+Conjugation+as+a+Strategy+for+in+Vivo+Target+Protein+Degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0lgcINc1mSG-ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520Conjugation%2520as%2520a%2520Strategy%2520for%2520in%2520Vivo%2520Target%2520Protein%2520Degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span>. <i>Angew. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1002/ange.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1002%2Fange.201507634" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=818-821&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+Design+for+the+Degradation+of+Oncogenic+BCR-ABL&doi=10.1002%2Fange.201507634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fange.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520Design%2520for%2520the%2520Degradation%2520of%2520Oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%26date%3D2016%26volume%3D128%26spage%3D818%26epage%3D821%26doi%3D10.1002%2Fange.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span>. <i>Cell Chemical Biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.-T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.-H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+Chemoproteomic+Approach+to+Query+the+Degradable+Kinome+Using+a+Multi-kinase+Degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.-T.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.-H.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520Chemoproteomic%2520Approach%2520to%2520Query%2520the%2520Degradable%2520Kinome%2520Using%2520a%2520Multi-kinase%2520Degrader%26jtitle%3DCell%2520Chemical%2520Biology%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhW9FTFZNzSAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.%0AH.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-+N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-+N4-%282-%28isopropylsulfonyl%29phenyl%29+pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-%2520N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-%2520N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529%2520pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span> <span> </span><span class="NLM_article-title">Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2140</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-10-2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=21415216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2140-2148&author=K.+Takezawaauthor=I.+Okamotoauthor=K.+Nishioauthor=P.+A.+Janneauthor=K.+Nakagawa&title=Role+of+ERK-BIM+and+STAT3-Survivin+Signaling+Pathways+in+ALK+Inhibitor-Induced+Apoptosis+in+EML4-ALK-Positive+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer</span></div><div class="casAuthors">Takezawa, Ken; Okamoto, Isamu; Nishio, Kazuto; Jaenne, Pasi A.; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2140-2148</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE:EML4-ALK (echinoderm microtubule-assocd. protein-like 4 anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer.  The purpose of the present study was to characterize the mechanism of malignant transformation by EML4-ALK.  Exptl. Design: We established NIH 3T3 cells that stably express variant 1 or 3 of EML4-ALK and examd. the signaling mols. that function downstream of EML4-ALK.  RESULTS: Forced expression of EML4-ALK induced marked activation of extracellular signal-regulated kinase (ERK) and STAT3, but not that of AKT.  Inhibition of ERK or STAT3 signaling resulted in substantial attenuation of the proliferation of cells expressing either variant of EML4-ALK, suggesting that these signaling pathways function downstream of EML4-ALK in lung cancer cells.  The specific ALK inhibitor TAE684 induced apoptosis that was accompanied both by upregulation of BIM, a proapoptotic member of the Bcl-2 family, and by downregulation of survivin, a member of the inhibitor of apoptosis protein (IAP) family, in EML4-ALK-expressing NIH 3T3 cells as well as in H3122 human lung cancer cells harboring endogenous EML4-ALK.  Depletion of BIM and overexpression of survivin each inhibited TAE684-induced apoptosis, suggesting that both upregulation of BIM and downregulation of survivin contribute to TAE684-induced apoptosis in EML4-ALK-pos. lung cancer cells.  Furthermore, BIM and survivin expression was found to be independently regulated by ERK and STAT3 signaling pathways, resp.  CONCLUSIONS: ALK inhibitor-induced apoptosis is mediated both by BIM upregulation resulting from inhibition of ERK signaling as well as by survivin downregulation resulting from inhibition of STAT3 signaling in EML4-ALK-pos. lung cancer cells.  Clin Cancer Res; 17(8); 2140-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7tzBYeSL6fbVg90H21EOLACvtfcHk0lgtEtU2uuksBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgsL0%253D&md5=218323843787c0a53794d661533d730f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2798%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DRole%2520of%2520ERK-BIM%2520and%2520STAT3-Survivin%2520Signaling%2520Pathways%2520in%2520ALK%2520Inhibitor-Induced%2520Apoptosis%2520in%2520EML4-ALK-Positive%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2140%26epage%3D2148%26doi%3D10.1158%2F1078-0432.CCR-10-2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0ljPzzOWxnsL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squillace, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadworny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miret, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5538</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+Potent+ALK+Inhibitor+Brigatinib+%28AP26113%29+Overcomes+Mechanisms+of+Resistance+to+First-+and+Second-Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0ljPzzOWxnsL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Potent%2520ALK%2520Inhibitor%2520Brigatinib%2520%2528AP26113%2529%2520Overcomes%2520Mechanisms%2520of%2520Resistance%2520to%2520First-%2520and%2520Second-Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span>; <span class="NLM_string-name">Huynh, T.</span>; <span class="NLM_string-name">Truong, A. M.</span>; <span class="NLM_string-name">Haber, M.</span>; <span class="NLM_string-name">Norris, M. D.</span></span> <i>ABC Transporters and Neuroblastoma</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier Inc.</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">125</span>, pp  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">170</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fbs.acr.2014.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=139-170&author=D.+M.+T.+Yu&author=T.+Huynh&author=A.+M.+Truong&author=M.+Haber&author=M.+D.+Norris&title=ABC+Transporters+and+Neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2014.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252Fbs.acr.2014.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26btitle%3DABC%2520Transporters%2520and%2520Neuroblastoma%26pub%3DElsevier%2520Inc%26date%3D2015%26volume%3D125%26spage%3D139%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chima, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunjan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretswell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangerfield, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span> <span> </span><span class="NLM_article-title">Reversal of P-Glycoprotein Mediated Multidrug Resistance by Novel Anthranilamide Derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00030-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2FS0960-894X%2899%2900030-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10098671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVylsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=595-600&author=M.+Roeauthor=A.+Folkesauthor=P.+Ashworthauthor=J.+Brumwellauthor=L.+Chimaauthor=S.+Hunjanauthor=I.+Pretswellauthor=W.+Dangerfieldauthor=H.+Ryderauthor=P.+Charlton&title=Reversal+of+P-Glycoprotein+Mediated+Multidrug+Resistance+by+Novel+Anthranilamide+Derivatives&doi=10.1016%2FS0960-894X%2899%2900030-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives</span></div><div class="casAuthors">Roe, Michael; Folkes, Adrian; Ashworth, Philip; Brumwell, Julie; Chima, Lal; Hunjan, Sukhjit; Pretswell, Ian; Dangerfield, Wendy; Ryder, Hamish; Charlton, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-600</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">We have synthesized and evaluated a series of anthranilamide based modulators of P-glycoprotein.  These studies have identified XR9576, a potent inhibitor of P-glycoprotein in vitro and in vivo.  The general synthesis and the SAR of these compds. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQO2OdePDQrVg90H21EOLACvtfcHk0lgxz6ed2eh0yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVylsrs%253D&md5=d1e096ea9c3a30d3574fbe9b92c657cb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900030-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900030-X%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DM.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DP.%26aulast%3DBrumwell%26aufirst%3DJ.%26aulast%3DChima%26aufirst%3DL.%26aulast%3DHunjan%26aufirst%3DS.%26aulast%3DPretswell%26aufirst%3DI.%26aulast%3DDangerfield%26aufirst%3DW.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DCharlton%26aufirst%3DP.%26atitle%3DReversal%2520of%2520P-Glycoprotein%2520Mediated%2520Multidrug%2520Resistance%2520by%2520Novel%2520Anthranilamide%2520Derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D595%26epage%3D600%26doi%3D10.1016%2FS0960-894X%2899%2900030-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Cross-Talk Between the Ubiquitin-Proteasome and Autophagy-Lysosome Systems</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2009.12.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.febslet.2009.12.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=20040365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs12msro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=1393-1398&author=V.+I.+Korolchukauthor=F.+M.+Menziesauthor=D.+C.+Rubinsztein&title=Mechanisms+of+Cross-Talk+Between+the+Ubiquitin-Proteasome+and+Autophagy-Lysosome+Systems&doi=10.1016%2Fj.febslet.2009.12.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems</span></div><div class="casAuthors">Korolchuk, Viktor I.; Menzies, Fiona M.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) and macroautophagy (hereafter called autophagy) were, for a long time, regarded as independent degradative pathways with few or no points of interaction.  This view started to change recently, in the light of findings that have suggested that ubiquitination can target substrates for degrdn. via both pathways.  Moreover, perturbations in the flux through either pathway have been reported to affect the activity of the other system, and a no. of mechanisms have been proposed to rationalize the link between the UPS and autophagy.  Here, the authors critically review these findings and outline some outstanding issues that still await clarification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreMYT4SAb8VLVg90H21EOLACvtfcHk0lgxz6ed2eh0yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs12msro%253D&md5=e95569a7bbf5978a284862669282e1db</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2009.12.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2009.12.047%26sid%3Dliteratum%253Aachs%26aulast%3DKorolchuk%26aufirst%3DV.%2BI.%26aulast%3DMenzies%26aufirst%3DF.%2BM.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DMechanisms%2520of%2520Cross-Talk%2520Between%2520the%2520Ubiquitin-Proteasome%2520and%2520Autophagy-Lysosome%2520Systems%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D1393%26epage%3D1398%26doi%3D10.1016%2Fj.febslet.2009.12.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.ccr.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=25065853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=207-221&author=H.-J.+Leeauthor=G.+Zhuangauthor=Y.+Caoauthor=P.+Duauthor=H.-J.+Kimauthor=J.+Settleman&title=Drug+Resistance+via+Feedback+Activation+of+Stat3+in+Oncogene-Addicted+Cancer+Cells&doi=10.1016%2Fj.ccr.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span></div><div class="casAuthors">Lee, Ho-June; Zhuang, Guanglei; Cao, Yi; Du, Pan; Kim, Hyo-Jin; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells.  We found that many drug-treated "oncogene-addicted" cancer cells engage a pos. feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response.  This was obsd. in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS.  Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacol. inhibition of MEK together with JAK and FGFR enhanced tumor regression.  These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9wv2-E6LTCLVg90H21EOLACvtfcHk0lgxz6ed2eh0yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I&md5=d180509b8b5a63331e8edbd0d2bf9a63</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-J.%26aulast%3DZhuang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DDrug%2520Resistance%2520via%2520Feedback%2520Activation%2520of%2520Stat3%2520in%2520Oncogene-Addicted%2520Cancer%2520Cells%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fj.ccr.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lgxz6ed2eh0yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+Ubiquitin+Ligase+Cereblon+to+Efficiently+Target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0litEQ69ONfSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520Ubiquitin%2520Ligase%2520Cereblon%2520to%2520Efficiently%2520Target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i15"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01655">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_87545"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01655">10.1021/acs.jmedchem.7b01655</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental methods for biochemical assays, cell culture, cellular assays, and expression proteomics; IC<sub>50</sub> values for biochemical assays and cellular IC<sub>50</sub> curves; dose–response Westerns; shRNA studies for ABCB1; expression proteomics in Kelly cells; cellular IC<sub>50</sub> values for Ba/F3 EML4-ALK cells (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_001.csv">jm7b01655_si_001.csv (2.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01655/suppl_file/jm7b01655_si_002.pdf">jm7b01655_si_002.pdf (6.69 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-9%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01655%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01655" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f279bd613c64","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
